Document:

EX-4.2

 REGISTRATION RIGHTS AGREEMENT 

dated as of 
 July 3, 2012 
 among 

ULTRA CLEAN HOLDINGS, INC., 
 AND 
 AIT HOLDING COMPANY LLC 

 TABLE OF CONTENTS 

 
  

					
	 	  	PAGE	 
		
	ARTICLE 1	  			
	DEFINITIONS	  			
		
	 Section 1.01. Definitions
	  	 	1	  
		
	ARTICLE 2	  			
	REGISTRATION RIGHTS	  			
		
	 Section 2.01. Demand Registration
	  	 	5	  
	 Section 2.02. Piggyback Registration
	  	 	8	  
	 Section 2.03. Shelf Registration
	  	 	9	  
	 Section 2.04. Registration Procedures
	  	 	10	  
	 Section 2.05. Indemnification by Parent
	  	 	17	  
	 Section 2.06. Indemnification by Participating Stockholders
	  	 	18	  
	 Section 2.07. Conduct of Indemnification Proceedings
	  	 	18	  
	 Section 2.08. Contribution
	  	 	19	  
	 Section 2.09. Participation in Public Offering
	  	 	20	  
	 Section 2.10. Other Indemnification
	  	 	21	  
	 Section 2.11. Cooperation by Parent
	  	 	21	  
	 Section 2.12. Transfer of Registration Rights
	  	 	21	  
		
	ARTICLE 3	  			
	BENEFIT OF RULE 144	  			
		
	 Section 3.01. Reports Under Exchange Act
	  	 	21	  
		
	ARTICLE 4	  			
	MISCELLANEOUS	  			
		
	 Section 4.01. Lockup Agreement
	  	 	22	  
	 Section 4.02. Binding Effect; Assignability; Benefit
	  	 	22	  
	 Section 4.03. Notices
	  	 	23	  
	 Section 4.04. Waiver; Amendment; Termination
	  	 	24	  
	 Section 4.05. Governing Law
	  	 	24	  
	 Section 4.06. Jurisdiction
	  	 	24	  
	 Section 4.07. WAIVER OF JURY TRIAL
	  	 	24	  
	 Section 4.08. Specific Enforcement
	  	 	25	  
	 Section 4.09. Counterparts; Effectiveness
	  	 	25	  
	 Section 4.10. Entire Agreement
	  	 	25	  
	 Section 4.11. Captions
	  	 	25	  

  
 i 

					
	 Section 4.12. Severability
	  	 	25	  
		
	 Exhibit A: Joinder Agreement
	  			

  
 ii 

 REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) dated as of July 3, 2012 is entered into between Ultra Clean
Holdings, Inc., a Delaware corporation (“Parent”), and AIT Holding Company LLC (“AIT”). 
 W I T N
E S S E T H : 
 WHEREAS, pursuant to the Agreement and Plan of Merger dated as of May 18, 2012 among Parent, American
Integration Technologies LLC, AIT and Element Merger Subsidiary, LLC, AIT has acquired securities of Parent (the “Merger Agreement”); 
 WHEREAS, AIT may make distributions of Parent’s securities to one or more of the members of AIT in transactions exempt from the registration requirements of the Securities Act or pursuant to an
effective registration statement; 
 WHEREAS, Parent, AIT, HLHZ AIT Holdings, L.L.C. (“HLHZ”) and Houlihan
Lokey, Inc. (“HL”) are entering into a Lockup and Standstill Agreement dated as of the date hereof (the “Lockup and Standstill Agreement”); 
 WHEREAS, the parties hereto desire to enter into this Agreement to govern certain of their rights, duties and obligations after consummation of the transactions contemplated by the Merger Agreement;

 NOW, THEREFORE, in consideration of the covenants and agreements contained herein, the parties hereto agree as follows:

 ARTICLE 1 
 DEFINITIONS 
 Section 1.01. Definitions. (a) The
following terms, as used herein, have the following meanings: 
 “Affiliate” means, with respect to any Person,
any other Person directly or indirectly controlling, controlled by or under common control with such Person, provided that no securityholder of Parent shall be deemed an Affiliate of any other securityholder solely by reason of any investment
in Parent. For the purpose of this definition, the term “control” (including, with correlative meanings, the terms “controlling”, “controlled by” and “under common control with”),
as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or
otherwise. 

  
 1 

 “Business Day” shall have the meaning ascribed to the same term in the
Merger Agreement. 
 “Common Stock” means the common stock, par value $0.001 per share, of Parent and any stock
into which such Common Stock may thereafter be converted or changed. 
 “Parent Securities” means (i) the
Common Stock, (ii) securities convertible into or exchangeable for Common Stock, (iii) any other equity or equity-linked security issued by Parent and (iv) options, warrants or other rights to acquire Common Stock or any other equity
or equity-linked security issued by Parent. 
 “Exchange Act” means the Securities Exchange Act of 1934, as
amended. 
 “FINRA” means the Financial Industry Regulatory Authority, Inc. 

“HL Funds” means HLHZ and HL, together with their Affiliates and any other fund managed by HL. 

“HL Fund Shares” means that number of Shares of the Stock Consideration (as defined in the Merger Agreement)
beneficially owned by the HL Funds or with respect to which the HL Funds would be deemed to have beneficial ownership for purposes of determining status as an affiliate of Parent pursuant to SEC rules and regulations. 

“Person” means an individual, corporation, partnership, limited liability company, association, trust or other entity or
organization, including a government or political subdivision or an agency or instrumentality thereof. 
 “Public
Offering” means an underwritten public offering of Registrable Securities of Parent pursuant to an effective registration statement under the Securities Act. 
 “Registrable Securities” means, at any time, any Shares and any securities issued or issuable in respect of such Shares by way of conversion, exchange, stock dividend, split or
combination, recapitalization, merger, consolidation, other reorganization or otherwise until (i) a registration statement covering such Shares has been declared effective by the SEC and such Shares have been disposed of pursuant to such
effective registration statement, except with respect to Shares that remain subject to the Rule 144 restrictions applicable to Parent’s affiliates following such disposition pursuant to such effective registration statement, (ii) such
Shares are sold under circumstances in which all of the applicable conditions of Rule 144 (or any similar provisions then in force) under the Securities Act are met or such securities may be sold pursuant to

  
 2 

 
Rule 144(b)(1) or (iii) such Shares are otherwise Transferred, Parent has delivered a new certificate or other evidence of ownership for such Shares not bearing the legend required pursuant
to this Agreement and such Shares may be resold without subsequent registration under the Securities Act. 

“Registration Expenses” means any and all expenses incident to the performance of or compliance with any registration or
marketing of securities, including without limitation all (i) registration and filing fees, and all other fees and expenses payable in connection with the listing of securities on any securities exchange or automated interdealer quotation
system, (ii) fees and expenses of compliance with any securities or “blue sky” laws (including reasonable fees and disbursements of counsel in connection with “blue sky” qualifications of the securities registered),
(iii) expenses in connection with the preparation, printing, mailing and delivery of any registration statements, prospectuses and other documents in connection therewith and any amendments or supplements thereto, (iv) security engraving
and printing expenses, (v) internal expenses of Parent (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), (vi) reasonable fees and disbursements of counsel for
Parent and customary fees and expenses for independent certified public accountants retained by Parent (including the expenses relating to any comfort letters or costs associated with the delivery by independent certified public accountants of any
comfort letters requested pursuant to Section 2.04(i)), (vii) reasonable fees and expenses of any special experts retained by Parent in connection with such registration, (viii) fees and expenses in connection with any review by the
FINRA of the underwriting arrangements or other terms of the offering, and all fees and expenses of any “qualified independent underwriter,” including the fees and expenses of any counsel thereto, (ix) fees and disbursements of
underwriters customarily paid by issuers or sellers of securities, but excluding any underwriting fees, discounts and commissions attributable to the sale of Registrable Securities, (x) costs of printing and producing any agreements among
underwriters, underwriting agreements, any “blue sky” or legal investment memoranda and any selling agreements and other documents in connection with the offering, sale or delivery of the Registrable Securities, (xi) transfer
agents’ and registrars’ fees and expenses, (xii) expenses relating to any analyst or investor presentations or any “road shows” undertaken in connection with the registration, marketing or selling of the Registrable
Securities, (xiii) fees and expenses payable in connection with any ratings of the Registrable Securities, including expenses relating to any presentations to rating agencies and (xiv) reasonable fees and expenses of one counsel of the
Registering Stockholders. For the avoidance of doubt, except as set forth in (xiv) above, Registration Expenses shall not include any out-of-pocket expenses of Requesting Stockholders, including, without limitation, expenses relating to any
counsel, accountant, custodian or attorney-in-fact for any such Requesting Stockholder and shall not include underwriter discounts or commissions. 

  
 3 

 “Requesting Stockholder” means (i) AIT so long as it is a Stockholder,
and (ii) any other Stockholder so long as such other Stockholder holds at least 25% of the Stock Consideration (as defined in the Merger Agreement), in each case, requesting a Demand Registration pursuant to Section 2.01 hereof.

 “Rule 144” means Rule 144 (or any successor provisions) under the Securities Act. 

“SEC” means the Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Shares” means shares of Common Stock. 
 “Shelf Registration Statement” means a “shelf” registration statement filed under the Securities Act providing for the registration of, and the sale and/or distribution on a
continuous or delayed basis by the holders of, the Registrable Securities pursuant to, Rule 415 under the Securities Act and/or any similar rule that may be adopted by the SEC, filed by Parent pursuant to the provisions of Section 2.03 of this
Agreement, including the prospectus contained therein, any amendments and supplements to such registration statement, including post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement.

 “Stockholder” means at any time, any Person (other than Parent) who shall then be a party to or bound by
this Agreement, so long as such Person shall “beneficially own” (as such term is defined in Rule 13d-3 of the Exchange Act) any Parent Securities. 
 “Transfer” means, with respect to any Parent Securities, (i) when used as a verb, to sell, distribute, assign, dispose of, exchange, pledge, encumber, hypothecate or otherwise
transfer such Parent Securities or any participation or interest therein, whether directly or indirectly, or agree or commit to do any of the foregoing and (ii) when used as a noun, a direct or indirect sale, distribution, assignment,
disposition, exchange, pledge, encumbrance, hypothecation, or other transfer of such Parent Securities or any participation or interest therein or any agreement or commitment to do any of the foregoing. 

(b) Each of the following terms is defined in the Section set forth opposite such term: 

 

			
	 Term
	  	Section
	Applicable Effectiveness Period	  	2.04(a)
	Applicable Efforts	  	2.04
	Damages	  	2.05

  
 4 

			
	 Term
	  	Section
	Demand Registration	  	2.01(a)
	Effectiveness Deadline Date	  	2.03(a)
	Indemnified Party	  	2.07
	Indemnifying Party	  	2.07
	Inspectors	  	2.04(n)
	Maximum Offering Size	  	2.01(e)
	Other Effectiveness Period	  	2.04(a)
	Participating Stockholders	  	2.04
	Piggyback Registration	  	2.02(a)
	Records	  	2.04(n)
	Registering Stockholders	  	2.01(a)(ii)
	Shelf Effectiveness Period	  	2.03(b)
	Shelf Registration	  	2.03(a)

 ARTICLE 2 
 REGISTRATION RIGHTS 
 Section 2.01. Demand
Registration. (a) If at any time from January 3, 2013 until July 3, 2016 (but only once), Parent shall have received a written request from a Requesting Stockholder that Parent effect the registration under the Securities Act of
all or any portion of such Requesting Stockholder’s Registrable Securities (provided, however, that any sales made pursuant to such request may only be effected up to the maximum number of shares that may be sold pursuant to the Lockup and
Standstill Agreement), and specifying the intended method of disposition thereof, then Parent shall promptly give notice of such requested registration (each such request shall be referred to herein as a “Demand Registration”) at
least 15 Business Days prior to the anticipated filing date of the registration statement relating to such Demand Registration to the other Stockholders and thereupon shall use reasonable best efforts to effect, as expeditiously as reasonably
practicable, and in any event within 45 days after such notice (provided, however, that such 45-day period may be extended by Parent for so long as necessary to reasonably promptly respond to any comments of the SEC to the satisfaction of the SEC),
the registration under the Securities Act of: 
 (i) all Registrable Securities for which the Requesting
Stockholder has requested registration under this Section 2.01 (for purposes of this Section 2.01, AIT may include in its Registrable Securities the Registrable Securities held by HL Funds), and 

(ii) subject to the restrictions set forth in Sections 2.01(e) and 2.02, all other Registrable Securities of the same
class as those requested to be registered by the Requesting Stockholder that any other Stockholders 

  
 5 

 
with rights to request registration under Section 2.02 (all such Stockholders, together with the Requesting Stockholder, the “Registering Stockholders”) have requested
Parent to register by request received by Parent within 15 Business Days after such Stockholders receive Parent’s notice of the Demand Registration, 
 all to the extent necessary to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the Registrable Securities so to be registered, provided that Parent shall
not be obligated to effect a Demand Registration unless (i) the aggregate gross proceeds expected to be received from the sale of the Registrable Securities requested to be included in such Demand Registration equals or exceeds $5,000,000 or
(ii) the Demand Registration relates to a Distribution (as defined in the Merger Agreement). In no event shall Parent be required to effect more than one Demand Registration hereunder. Parent shall not be required to effect a Demand
Registration pursuant to Rule 415 (or its successor provision) under the Securities Act. 
 (b) Promptly after the expiration of
the 15-Business Day period referred to in Section 2.01(a)(ii), Parent will notify all Registering Stockholders of the identities of the other Registering Stockholders and the number of shares of Registrable Securities requested to be included
therein. At any time prior to the effective date of the registration statement relating to such registration, the Requesting Stockholders may revoke such request, without liability to any of the other Registering Stockholders, by providing a notice
to Parent revoking such request; provided, that such notice is received by Parent a reasonable time before the registration statement applicable to such registration becomes effective such that Parent may amend such registration statement to
remove such Registering Stockholder prior to effectiveness. 
 (c) Parent shall be liable for and pay all Registration Expenses
in connection with any Demand Registration, regardless of whether such registration is effected. 
 (d) A Demand Registration
shall not be deemed to have occurred unless the registration statement relating thereto (i) has become effective under the Securities Act and (ii) has remained effective for a period of at least 90 days (or such shorter period in which all
Registrable Securities of the Registering Stockholders included in such registration have actually been sold thereunder), provided that such registration statement shall not be considered a Demand Registration if, after such registration
statement becomes effective, (1) such registration statement is interfered with by any stop order, injunction or other order or requirement of the SEC or other governmental agency or court and (2) less than 90% of the Registrable
Securities included in such registration statement have been sold thereunder. 

  
 6 

 (e) If a Demand Registration involves a Public Offering and the managing underwriter advises
Parent and the Requesting Stockholder that, in its view, the number of shares of Registrable Securities requested to be included in such registration (including any securities that Parent proposes to be included that are not Registrable Securities)
exceeds the largest number of shares that can be sold without having an adverse effect on such offering, including the price at which such shares can be sold (the “Maximum Offering Size”), Parent shall include in such registration,
in the priority listed below, up to the Maximum Offering Size: 
 (i) First, all Registrable Securities requested
to be registered by the Requesting Stockholder; 
 (ii) second, all other Registrable Securities requested to be
included in such registration by any Registering Stockholder (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such other Stockholders on the basis of the relative number of Registrable Securities so
requested to be included in such registration by each such Stockholders); and 
 (iii) third, any securities
proposed to be registered by Parent. 
 For purposes of this Section 2.01, a registration shall not be counted as
“effected” if, as a result of an exercise of the underwriter’s cutback provisions in this Section 2.01(e), fewer than 60% of the total number of Registrable Securities that Stockholders requested to be included in such
registration statement are actually included. 
 (f) Upon notice to each Registering Stockholder, Parent may postpone effecting
a registration pursuant to this Section 2.01 on one occasion during any period of twelve consecutive months for a reasonable time specified in the notice but not exceeding 75 days (which period may not be extended or renewed), if Parent shall
furnish to the Requesting Stockholder a certificate signed by the chief executive officer of Parent stating that in the good faith judgment of Parent, it would be materially detrimental to Parent or its stockholders for such registration to proceed
as expeditiously as possible because such action would (x) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Parent; (y) require premature disclosure of material
information that the Parent has a bona fide business purpose for preserving as confidential; or (z) render the Parent unable to comply with requirements under the Securities Act or Exchange Act; provided, however, that the Parent shall
not register any securities for its own account or that of any other stockholder during such 75-day period. 

  
 7 

 Section 2.02. Piggyback Registration. (a) If at any time Parent proposes to
register any Parent Securities under the Securities Act (other than a registration on Form S-8 or S-4, or any successor forms, relating to Common Stock issuable upon exercise of employee stock options or in connection with any employee benefit or
similar plan of Parent or in connection with a direct or indirect acquisition by Parent of another Person), whether or not for sale for its own account, other than pursuant to Section 2.03, Parent shall each such time give notice as soon as
practicable (but in no event less than 10 Business Days prior to the anticipated filing date of the registration statement relating to such registration) to each Stockholder, which notice shall set forth such Stockholder’s rights under this
Section 2.02 and shall offer such Stockholder the opportunity to include in such registration statement the number of Registrable Securities of the same class or series as those proposed to be registered as each such Stockholder may request (a
“Piggyback Registration”), subject to the provisions of Section 2.02(b). Upon the request of any such Stockholder made within 15-Business Days after the receipt of notice from Parent (which request shall specify the number of
Registrable Securities intended to be registered by such Stockholder), Parent shall use its commercially reasonable efforts to effect the registration under the Securities Act of all Registrable Securities that Parent has been so requested to
register by all such Stockholders, to the extent requisite to permit the disposition of the Registrable Securities to be so registered, provided that: (i) if such registration involves a Public Offering, all such Stockholders requesting
to be included in Parent’s registration must sell their Registrable Securities to the underwriters selected as provided herein on the same terms and conditions as apply to Parent or any other Requesting Stockholders, as applicable, and
(ii) if, at any time after giving notice of its intention to register any Parent Securities pursuant to this Section 2.02(a) and prior to the effective date of the registration statement filed in connection with such registration, Parent
shall determine for any reason not to register such securities, Parent shall give notice to all such Stockholders and, thereupon, shall be relieved of its obligation to register any Registrable Securities in connection with such registration. Parent
shall pay all Registration Expenses in connection with each Piggyback Registration. 
 (b) If a Piggyback Registration involves
a Public Offering (other than any Demand Registration, in which case the provisions with respect to priority of inclusion in such offering set forth in Section 2.01(e) shall apply), and the managing underwriter advises Parent that, in its view,
the number of Shares that Parent and such Stockholders intend to include in such registration exceeds the Maximum Offering Size, Parent shall include in such registration, in the following priority, up to the Maximum Offering Size: 

(i) first, so much of the Parent Securities proposed to be registered for the account of Parent as would not cause the
offering to exceed the Maximum Offering Size; 

  
 8 

 (ii) second, all Registrable Securities requested to be included in such
registration by any other Stockholders pursuant to Section 2.02 (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Stockholders on the basis of the relative number of shares of Registrable
Securities so requested to be included in such registration by such Stockholders); and 
 (iii) third, all other
securities with registration rights properly requested to be included in such registration (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such other stockholders on the basis of the relative number
of shares of registrable securities so requested to be included in such registration by such stockholders). 
 (c) Parent shall
be liable for and pay all Registration Expenses in connection with any Piggyback Registration, regardless of whether such registration is effected. 
 Section 2.03. Shelf Registration. (a) Parent shall file with the SEC a Shelf Registration Statement covering (i) one or more Distributions (as defined in the Merger Agreement) and
(ii) the resale of the HL Fund Shares by AIT and/or the HL Funds; provided, however, that the number of HL Fund Shares that may be resold pursuant to this subsection (ii) shall not exceed that number of shares that, following such
resale, would result in the HL Fund Shares being nine and nine-tenths percent (9.9%) or less of the number of shares of Parent Common Stock then issued and outstanding; provided, further, that the number of Shares that may be resold
pursuant to subsections (i) and (ii) shall be subject to the restrictions set forth in the Lockup and Standstill Agreement (the “Shelf Registration”). Parent shall use its reasonable best efforts to cause such Shelf
Registration Statement to be declared effective under the Securities Act no later than the six-month anniversary of the date of this Agreement (the “Effectiveness Deadline Date”). The Shelf Registration Statement shall be on Form
S-3 (except if Parent is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form for such purpose) and shall contain (except if otherwise required by the
Act) a plan of distribution reasonably agreed upon by Parent and AIT. 
 (b) Parent shall use its reasonable best efforts to
keep the Shelf Registration Statement continuously effective in order to permit the prospectus included in the Shelf Registration Statement to be usable by Stockholders as set forth in Section 2.03(a) until the earlier of (i) the eighteen
month anniversary of the date of this Agreement and (ii) 90 days following such date that the number of HL Fund Shares is less than ten percent (10%) of the number of shares of Parent Common Stock issued and outstanding (such period being
referred to herein as the “Shelf Effectiveness Period”). 

  
 9 

 (c) Parent shall be liable for and pay all Registration Expenses in connection with the
Shelf Registration Statement. 
 Section 2.04. Registration Procedures. With respect to any registration under
Section 2.01, Section 2.02 or Section 2.03, subject to the provisions of such Sections, Parent shall use its (i) reasonable best efforts with respect to its obligations under Section 2.01 and Section 2.03 and
(ii) commercially reasonable efforts with respect to its obligations under Section 2.02 (collectively, “Applicable Efforts”) to effect the registration of such Registrable Securities on behalf of such Stockholders
participating in such registration (the “Participating Stockholders”) in accordance with the intended method of disposition thereof as expeditiously as reasonably practicable, and, in connection with any such request: 

(a) With respect to a registration pursuant to Section 2.01 or Section 2.02, Parent shall as expeditiously as reasonably
practicable prepare and file with the SEC a registration statement on any form for which Parent then qualifies or that counsel for Parent shall deem appropriate and which form shall be available for the sale of the Registrable Securities to be
registered thereunder in accordance with the intended method of distribution thereof, and use Applicable Efforts to cause such filed registration statement to become and remain effective for a period of not less than 90 days pursuant to a
registration statement in accordance with Section 2.01 hereof (or such shorter period in which all of the Registrable Securities of the Participating Stockholders included in such registration statement shall have actually been sold thereunder)
(the “Other Effectiveness Period”, with each Other Effectiveness Period and Shelf Effectiveness Period referred to herein as an “Applicable Effectiveness Period”). 

(b) Parent shall furnish to Stockholder and any underwriters no fewer than five Business Days prior to the initial filing of the
registration statement, a copy of such registration statement, and shall furnish to such Participating Stockholders and underwriters, if any, no fewer than two Business Days prior to the filing of any amendment or supplement to the prospectus
included therein, a copy of such amendment or supplement, which documents shall be subject to the reasonable review of such stockholders and underwriters and their respective counsel, and shall not file with the SEC any such documents to which such
Participating Stockholders or underwriters, if any, shall reasonably object; provided, however, that Parent shall not have any obligation so to modify any information if Parent reasonably expects that so doing would cause the prospectus to
contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. 

  
 10 

 (c) During an Applicable Effectiveness Period, Parent shall promptly take such action as may
be necessary so that (i) each of the registration statement and any amendment thereto and the prospectus contained therein and any amendment or supplement thereto (and each report or other document incorporated by reference therein in each
case) complies in all material respects with the Securities Act and the Exchange Act and the rules and regulations thereunder, (ii) each of the registration statement and any amendment thereto does not, when it becomes effective, contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading and (iii) each of the
prospectus and any amendment or supplement to the prospectus does not at any time during the Applicable Effectiveness Period include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. Without limiting the foregoing, after the filing of the registration statement, Parent shall: (x) cause the registration statement and the related prospectus
to be promptly amended and/or supplemented by any required amendment and/or supplement, and, as so amended and/or supplemented, to be filed pursuant to Rule 424 under the Securities Act, as may be necessary to comply with the Securities Act in order
to enable the disposition of the securities covered by such registration statement; (y) comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such registration statement during
the applicable period in accordance with the intended methods of disposition by the such Stockholders thereof set forth in such registration statement or supplement to such prospectus; and (z) take all reasonable actions required to prevent the
entry of a stop order or to remove it if entered. 
 (d) Parent shall as promptly as practicable advise each Stockholder:

 (i) when the registration statement and any amendment thereto or a supplement to any prospectus forming a part
of such registration statement has been filed with the SEC and when the registration statement or any post-effective amendment thereto has become effective; 
 (ii) when the SEC notifies Parent whether there will be a “review” of such registration statement and whenever the SEC comments in writing on such registration statement, including the documents
incorporated by reference therein (Parent shall provide true and complete copies of such comments and all written responses thereto to each of the Participating Stockholders, as well as any underwriter, and shall provide, no fewer than five Business
Days prior to the filing of any response to any comment that pertains to the Participating Stockholders or any underwriter or to the plan of distribution, and shall reflect in each such response when

  
 11 

 
so filed with the SEC, such comments as such Participating Stockholders reasonably may propose, but not information which Parent believes would constitute material and non-public information;
provided, that Parent shall not have any obligation so to include any such comments if Parent reasonably expects that so doing would cause the registration statement or such response to the SEC to contain an untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading); 
 (iii) of the occurrence of an event requiring the preparation of a supplement or amendment to such prospectus (and Parent shall as promptly as practicable prepare and make available to each such
Stockholder and file with the SEC any such supplement or amendment); 
 (iv) of the issuance by the SEC of any
stop order suspending the effectiveness of the registration statement or the initiation of any proceedings for such purpose; 
 (v) of the receipt by Parent of any notification with respect to the suspension of the qualification of the securities included in the registration statement for sale in any jurisdiction or the initiation
of any proceeding for such purpose; 
 (vi) if, at any time, the representations and warranties of Parent in any
applicable underwriting agreement cease to be true and correct in all material respects; and 
 (vii) if changes
in the registration statement or the prospectus contained therein are required in order that the registration statement and prospectus do not contain an untrue statement of a material fact and do not omit to state a material fact required to be
stated therein or necessary to make the statements therein (in the case of the prospectus, in light of the circumstances under which they were made) not misleading. 
 (e) Parent shall use Applicable Efforts to prevent the issuance, and if issued to obtain the withdrawal, of any stop order or other order suspending the effectiveness of the registration statement or the
use of any prospectus or preliminary prospectus as promptly as practicable. 
 (f) Parent shall use Applicable Efforts to:
(i) register or qualify the Registrable Securities covered by such registration statement under such other securities or “blue sky” laws of such jurisdictions in the United States as any Participating Stockholder reasonably (in light
of such Stockholder’s intended plan of distribution) requests; (ii) cause such Registrable Securities to be registered with or approved by such other governmental agencies or authorities as may be

  
 12 

 
necessary by virtue of the business and operations of Parent; (iii) keep such registrations or qualifications in effect and comply with such laws so as to permit the continuance of offers
and sales in such jurisdictions for the Applicable Effectiveness Period; and (iv) do any and all other acts and things that may be reasonably necessary or advisable in connection with a registration of shares to enable such Participating
Stockholders to consummate the disposition of the Registrable Securities owned by such Stockholder, provided that Parent shall not be required to: (A) qualify generally to do business in any jurisdiction where it would not otherwise be
required to qualify but for this Section 2.04(f); (B)subject itself to taxation in any such jurisdiction; or (C) consent to general service of process in any such jurisdiction, unless the Parent is already subject to service in such
jurisdiction and except as may be required by the Securities Act; 
 (g) Parent shall cooperate and assist in any filings
required to be made with FINRA and each securities exchange, if any, on which any of Parent’s securities are then listed or quoted and on each inter-dealer quotation system on which any of Parent’s securities are then quoted, and in the
performance of any due diligence investigation by any underwriter or dealer manager (including any “qualified independent underwriter”) that is required to be retained in accordance with FINRA rules. 

(h) With respect to Section 2.01 only, the underwriter or underwriters in connection with any Public Offering shall be selected by
the Requesting Stockholder, subject only to the reasonable approval of the Parent. With respect to Section 2.03(a)(ii) only, the underwriter or underwriters in connection with any Public Offering shall be selected by the Participating
Stockholders, subject only to the reasonable approval of Parent. In connection with any Public Offering, Parent shall enter into customary agreements (including an underwriting agreement in customary form) and take such other actions as are required
in order to expedite or facilitate the disposition of such Registrable Securities in any such Public Offering, including, if applicable, the engagement of a “qualified independent underwriter” in connection with the qualification of the
underwriting arrangements with FINRA. 
 (i) As promptly as practicable, Parent shall: (A) provide each underwriter, each
Participating Stockholder, any accounting firm and any other agent or counsel retained by such holders or any such underwriter the opportunity to participate in the preparation of such registration statement, each prospectus included therein or
filed with the SEC, and each amendment or supplement thereto; (B) make such representations and warranties to the Participating Stockholders and to the underwriters, in form, substance and scope as are customarily made by issuers to selling
stockholders and underwriters in comparable underwritten offerings of equity securities; (C) obtain opinions of counsel to Parent (which counsel and opinions (in form, scope and substance)

  
 13 

 
shall be reasonably satisfactory to the underwriters) addressed to the underwriters and each requesting Participating Stockholder, covering such matters as are customarily covered in opinions
requested in comparable underwritten offerings of equity securities (it being agreed that the matters to be covered shall include, without limitation, as of the date of the opinion and as of the date of effectiveness or the date of the most recent
post-effective amendment thereto, as the case may be, and as of the date of the prospectus, comment of such counsel as to the absence, to such counsel’s knowledge, from the registration statement and the prospectus contained therein, including
the documents incorporated by reference therein, of an untrue statement of a material fact or the omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of the prospectus, in light of the
circumstances under which they were made,) not misleading); (D) in connection with any underwritten offering, obtain “cold comfort” letters and updates thereof from the independent registered public accounting firm of Parent (and, if
necessary, from the independent registered public accounting firm of any subsidiary of Parent or of any business acquired by Parent for which financial statements and financial data are, or are required to be, included in the registration
statement), addressed to each requesting Participating Stockholder (if such Stockholder has provided such letter, representations or documentation, if any, required for such cold comfort letter to be so addressed) and the underwriters, in customary
form and covering matters of the type customarily covered in “cold comfort” letters in connection with comparable underwritten offerings; (E) deliver such other documents and certificates as may be reasonably requested by any
Participating Stockholders and the underwriters, if any, including without limitation certificates to evidence compliance with any conditions contained in the underwriting agreement or other agreements entered into by Parent in connection therewith;
and (F) cause the senior executive officers of Parent to facilitate, cooperate with, and participate in each proposed offering contemplated herein and customary selling efforts related thereto, except to the extent that such participation
materially interferes with the management of Parent’s business; provided that the Applicable Effectiveness Period shall be increased by the period of time that management cannot so participate. No registration shall be deemed to have been
effective if the conditions to closing in the underwriting agreement are not satisfied by reason of a wrongful act, misrepresentation or breach of such underwriting agreement. 
 (j) Parent shall use Applicable Efforts to comply with all applicable rules and regulations of the SEC and make generally available to its security holders, as soon as reasonably practicable, but no later
than 90 days after the end of the 12-month period beginning with the first day of Parent’s first quarter commencing after the effective date of the applicable registration statement, an earnings statement satisfying the provisions of
Section 11(a) of the Securities Act and the rules and regulations promulgated thereunder and covering a period of 12 months, beginning with the first month after the effective date of the registration statement. 

  
 14 

 (k) Parent may require each Participating Stockholder promptly to furnish in writing to
Parent such information regarding such Stockholder, the plan of distribution of the Registrable Securities and other information as Parent may from time to time reasonably request and such other information as may be legally required in connection
with such registration. 
 (l) Parent shall use its Applicable Efforts to list all Registrable Securities covered by such
registration statement on any securities exchange or quotation system on which any of the same class of Parent Securities are then listed or traded. 
 (m) Parent shall provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case
not later than the effective date of such registration. 
 (n) Upon execution of confidentiality agreements in form and
substance reasonably satisfactory to Parent, Parent shall, as promptly as practicable, (A) make reasonably available for inspection by requesting Participating Stockholders, any underwriter participating in any disposition pursuant to the
Registration, one accountant and any other professional retained by such holders or any such underwriter (collectively, the “Inspectors”) all relevant financial and other records, pertinent corporate documents and properties of
Parent and its subsidiaries (collectively, the “Records”) and (B) cause Parent’s officers, directors, employees and independent registered public accounting firm to make themselves reasonably available upon reasonable
notice and for reasonable periods of time to discuss the business of the Parent and to respond to appropriate questions and to supply all information reasonably requested by such holders or any such underwriter, accountant or professional in
connection with the registration (and the prospectus), in each case, as is customary for similar due diligence examinations; provided, however, that all records that Parent determines, in good faith, to be confidential and that it
notifies the Inspectors are confidential shall not be disclosed by the Inspectors unless (1) the disclosure of such Records is necessary to avoid or correct a misstatement or omission in such registration statement, (2) the release of such
Records is ordered pursuant to a subpoena or other order from a court of competent jurisdiction or disclosure is required by an official or representative of a governmental agency or authority or self-regulatory authority or stock exchange the rules
of which Parent is subject or (3) such Records become available to the public generally or through a third party without a breach of an obligation of confidentiality. Each Stockholder further agrees that, upon learning that disclosure of such
Records is sought in a court of competent 

  
 15 

 
jurisdiction or otherwise, it shall give notice to Parent and assist Parent, at Parent’s expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential.

 (o) Each such Participating Stockholder agrees that, upon receipt of any notice from Parent of the happening of any event of
the kind described in Section 2.04(d)(iii), Section 2.04(d)(iv), Section 2.04(d)(v) or Section 2.04(d)(vii), such Stockholder shall forthwith discontinue disposition of Registrable Securities pursuant to the registration
statement covering such Registrable Securities until such Stockholder’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 2.04(c), and, if so directed by Parent, such Stockholder shall deliver to
Parent all copies, other than any permanent file copies then in such Stockholder’s possession, of the most recent prospectus covering such Registrable Securities at the time of receipt of such notice. If Parent shall give such notice, Parent
shall extend the period during which such registration statement shall be maintained effective by the number of Business Days during the period from and including the date of the giving of such notice to the date when Parent shall make available to
such Stockholder a prospectus supplemented or amended to conform with the requirements of Section 2.04(c) and/or when such suspension is removed, as the case may be. 
 (p) Parent shall take all other reasonable steps necessary or appropriate to effect the registration, and to assist the Stockholder in effecting the distribution, offering and sale of the Registrable
Securities covered by the registration statement contemplated hereby, including, without limitation: 
 (i)
furnishing to each Participating Stockholder and each underwriter, if any, without charge, as many conformed copies as such Stockholder or underwriter may reasonably request of the applicable Registration Statement and any amendment or
post-effective amendment thereto, including financial statements and schedules; 
 (ii) delivering to each
Participating Stockholder and each underwriter, if any, without charge, as many copies of the applicable Prospectus (including each preliminary prospectus) and any amendment or supplement thereto as such Stockholder or underwriter may reasonably
request (it being understood that Parent consents to the use of such Prospectus or any amendment or supplement thereto by each Participating Stockholder and the underwriter(s), if any, in connection with the offering and sale of the Registrable
Securities covered by such Prospectus or any amendment or supplement thereto); and 
 (iii) in connection with
any sale of Registrable Securities that will result in such securities no longer being Registrable Securities, 

  
 16 

 
cooperate with each Participating Stockholder and the managing underwriter(s), if any, to facilitate the timely preparation and delivery of certificates or security entitlements representing
Registrable Securities to be sold and not bearing any restrictive Securities Act legends; and to register such Registrable Securities in such denominations and such names as such Participating Stockholder or the underwriter(s), if any, may request
at least two Business Days prior to such sale of Registrable Securities. 
 Section 2.05. Indemnification by Parent.
Parent agrees to indemnify and hold harmless each Registering Stockholder holding Registrable Securities covered by a registration statement, its officers, directors, partners, members, owners, legal counsel and accountants and each Person, if
any, who controls such Stockholder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act from and against any and all losses, claims, damages, liabilities and expenses (including reasonable expenses of
investigation and reasonable attorneys’ fees and expenses) (“Damages”) caused by or relating to any untrue statement or alleged untrue statement of a material fact contained in any registration statement or prospectus relating
to the Registrable Securities (as amended or supplemented if Parent shall have furnished any amendments or supplements thereto) or any preliminary prospectus, or caused by or relating to any omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such Damages are caused by or related to any such untrue statement or omission or alleged untrue statement or omission so made based
upon information furnished in writing to Parent by such Stockholder or on such Stockholder’s behalf expressly for use therein, provided that the foregoing indemnity with respect to any preliminary prospectus or prospectus shall not apply
to the extent that any Damages result from the fact that a current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) was not sent or given to the Person asserting such Damages at or prior to the written
confirmation of the sale of the Registrable Securities to such Person, if it is determined that Parent has provided such prospectus to such Stockholder and it was the responsibility of such Stockholder to provide such Person with a current copy of
the prospectus (or such amended or supplemented prospectus, as the case may be), and such current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) would have cured the defect giving rise to such Damages. Parent
also agrees to indemnify any underwriters of the Registrable Securities, their officers and directors and each Person who controls such underwriters within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act
on substantially the same basis as that of the indemnification of the Stockholders provided in this Section 2.05. 

  
 17 

 Section 2.06. Indemnification by Participating Stockholders. Each Registering
Stockholder holding Registrable Securities included in any registration statement, severally and not jointly, agrees to indemnify and hold harmless Parent, its officers and directors and each Person, if any, who controls Parent within the meaning of
either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from Parent to such Stockholder, but only (i) with respect to information furnished in writing by such Stockholder
or on such Stockholder’s behalf expressly for use in any registration statement or prospectus relating to the Registrable Securities, or any amendment or supplement thereto, or any preliminary prospectus or (ii) to the extent that any
Damages result from the fact that a current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) was not sent or given to the Person asserting any such Damages at or prior to the written confirmation of the sale of
the Registrable Securities to such Person, if it is determined that it was the responsibility of such Stockholder to provide such Person with a current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) and such
current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) would have cured the defect giving rise to such loss, claim, damage, liability or expense. Each such Stockholder also agrees to indemnify and hold
harmless underwriters of the Registrable Securities, their officers and directors and each Person who controls such underwriters within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act on
substantially the same basis as that of the indemnification of Parent provided in this Section 2.06. As a condition to including Registrable Securities in any registration statement filed in accordance with Article 2, Parent may require that it
shall have received an undertaking reasonably satisfactory to it from any underwriter to indemnify and hold it harmless to the extent customarily provided by underwriters with respect to similar securities. 

Section 2.07. Conduct of Indemnification Proceedings. If any proceeding (including any governmental investigation) shall be
instituted involving any Person in respect of which indemnity may be sought pursuant to this Article 2, such Person (an “Indemnified Party”) shall promptly notify the Person against whom such indemnity may be sought (the
“Indemnifying Party”) in writing and the Indemnifying Party, upon the request of the Indemnified Party, shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Party, and
shall assume the payment of all fees and expenses, provided that the failure of any Indemnified Party so to notify the Indemnifying Party shall not relieve the Indemnifying Party of its obligations hereunder except to the extent that the
Indemnifying Party is materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Party unless (i) the Indemnifying Party and the 

  
 18 

 
Indemnified Party shall have mutually agreed to the retention of such counsel or (ii) in the reasonable judgment of such Indemnified Party representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. It is understood that, in connection with any proceeding or related proceedings in the same jurisdiction, the Indemnifying Party shall not be liable for the
reasonable fees and expenses of more than one separate firm of attorneys (in addition to any local counsel) at any time for all such Indemnified Parties, and that all such fees and expenses shall be reimbursed as they are incurred. In the case of
any such separate firm for the Indemnified Parties, such firm shall be designated in writing by the Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any proceeding effected without its written consent, but if
settled with such consent, or if there be a final judgment for the plaintiff, the Indemnifying Party shall indemnify and hold harmless such Indemnified Parties from and against any loss or liability (to the extent stated above) by reason of such
settlement or judgment. Without the prior written consent of the Indemnified Party, no Indemnifying Party shall effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Party is or could have been a party and
indemnity could have been sought hereunder by such Indemnified Party. 
 Section 2.08. Contribution. If the
indemnification provided for in this Article 2 is unavailable to the Indemnified Parties in respect of any Damages, then each such Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by
such Indemnified Party as a result of such Damages (i) as between Parent and the Registering Stockholders holding Registrable Securities covered by a registration statement, on the one hand, and the underwriters on the other, in such proportion
as is appropriate to reflect the relative benefits received by Parent and such Stockholders, on the one hand, and the underwriters, on the other, from the offering of the Registrable Securities, or if such allocation is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits but also the relative fault of Parent and such Stockholders, on the one hand, and of such underwriters, on the other, in connection with the statements or omissions
that resulted in such Damages, as well as any other relevant equitable considerations and (ii) as between Parent, on the one hand, and each such Stockholder, on the other, in such proportion as is appropriate to reflect the relative fault of
Parent and of each such Stockholder in connection with such statements or omissions, as well as any other relevant equitable considerations. The relative benefits received by Parent and such Stockholders, on the one hand, and such underwriters, on
the other, shall be deemed to be in the same proportion as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by Parent and such Stockholders bear to the total underwriting
discounts and commissions received by such underwriters, in each case as set forth in the table on the cover page of the prospectus. The relative fault of Parent 

  
 19 

 
and such Stockholders, on the one hand, and of such underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by Parent and such Stockholders or by such underwriters. The relative fault of Parent, on the one hand, and of each such Stockholder on the other shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by such party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 Parent
and the Stockholders agree that it would not be just and equitable if contribution pursuant to this Section 2.08 were determined by pro rata allocation (even if the underwriters were treated as one entity for such purpose) or by any other
method of allocation that does not take account of the equitable considerations referred to in the immediately preceding paragraph. The amount paid or payable by an Indemnified Party as a result of the Damages referred to in the immediately
preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 2.08, (x) no underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Registrable Securities underwritten by it and distributed to
the public were offered to the public exceeds the amount of any Damages that such underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, and no Registering Stockholder
shall be required to contribute any amount in excess of the amount by which the total price at which the Registrable Securities of such Stockholder were offered to the public (less underwriters’ discounts and commissions) exceeds the amount of
any Damages that such Stockholder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission; (y) no Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and (z) in no event shall a Stockholder’s liability pursuant to this Section 2.07,
when combined with the amounts paid or payable by such Stockholder pursuant to Section 2.06, exceed the proceeds from the offering received by such Stockholder (net of any underwriter’s discounts and commissions and other selling expenses
paid by such Stockholder), except in the case of willful misconduct or fraud by such Stockholder. 
 Section 2.09.
Participation in Public Offering. No Person may participate in any Public Offering hereunder unless such Person (a) agrees to sell such 

  
 20 

 
Person’s securities on the basis provided in any underwriting arrangements approved by the Persons entitled hereunder to approve such arrangements and (b) completes and executes all
questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements and the provisions of this Agreement in respect of registration rights. 

Section 2.10. Other Indemnification. Indemnification similar to that specified herein (with appropriate modifications) shall
be given by Parent and each Registering Stockholder participating therein with respect to any required registration or other qualification of securities under any federal or state law or regulation or governmental authority other than the Securities
Act. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with Public Offering are in conflict with the foregoing provisions, the
provisions in the underwriting agreement shall control. 
 Section 2.11. Cooperation by Parent. If any Stockholder
shall transfer any Registrable Securities pursuant to Rule 144, Parent shall cooperate, to the extent commercially reasonable, with such Stockholder and shall provide to such Stockholder such information as such Stockholder shall reasonably request.

 Section 2.12. Transfer of Registration Rights. Subject to Section 4.02(b), a Stockholder may Transfer its
rights under this Article 2 if the Transferee will hold at least 25% of the Stock Consideration after such Transfer. Subject to the foregoing sentence, none of the rights of Stockholders under this Article 2 shall be assignable by any Stockholder to
any Person acquiring Securities in any Public Offering or pursuant to Rule 144. 
 ARTICLE 3 

BENEFIT OF RULE 144 
 Section 3.01. Reports Under Exchange Act. With a view to making available to the Stockholders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a
Stockholder to sell securities of Parent to the public without registration, Parent shall: 
 (a) make and keep available
adequate current public information, as those terms are understood and defined in Rule 144, at all times after the effective date of the registration statement filed by the Parent 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Parent
under the Securities Act and the Exchange Act; and 

  
 21 

 (c) furnish to any Stockholder, so long as the Stockholder owns any Registrable Securities,
forthwith upon request (i) to the extent accurate, a written statement by Parent that it has complied with the reporting requirements of Rule 144, the Securities Act, and the Exchange Act; and (ii) such information as may be reasonably
requested in availing any Stockholder of any rule or regulation of the SEC that permits the selling of any such securities without registration. 
 ARTICLE 4 
 MISCELLANEOUS 

Section 4.01. Lockup Agreement. Any rights granted to the Stockholders hereunder are granted and made expressly subject to
the Lockup and Standstill Agreement (as defined in the Merger Agreement) and Parent shall not be required to take any action which contravenes the terms of such Lockup and Standstill Agreement. 

Section 4.02. Binding Effect; Assignability; Benefit. (a) This Agreement shall inure to the benefit of and be binding
upon the parties hereto and their respective heirs, successors, legal representatives and permitted assigns. 
 (b) Neither this
Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by any party hereto pursuant to any Transfer of Parent Securities or otherwise, except that (i) following any Distribution (as
defined in the Merger Agreement) or one or more other distributions of Parent Securities by a Stockholder to its beneficial owners, (ii) following the Transfer of Parent Securities by a Stockholder to a transferee that is such
Stockholder’s Affiliate, spouse, ex-spouse, domestic partner, lineal descendant or antecedent, brother or sister, the adopted child or adopted grandchild, or the spouse or domestic partner of any child, grandchild or adopted grandchild of such
Stockholder, trust for the benefit of such Stockholder or those members of such Stockholder’s family specified in this subsection (b), and (iii) pursuant to Section 2.12; such Transferee may (unless already bound hereby) execute and
deliver to Parent an agreement to be bound by this Agreement in the form of Exhibit A hereto and shall thenceforth be a “Stockholder” for purposes of, and have the rights of a “Stockholder” under, this Agreement, provided
that any such Transfer pursuant to this Section 4.02(b) must be in accordance with the Lockup and Standstill Agreement. 
 (c) Nothing in this Agreement, expressed or implied, is intended to confer on any Person other than the parties hereto, and their respective heirs, successors, legal representatives and permitted assigns,
any rights, remedies, obligations or liabilities under or by reason of this Agreement. 

  
 22 

 Section 4.03. Notices. All notices, requests and other communications to any
party shall be in writing and shall be delivered in person, mailed by certified or registered mail, return receipt requested, or sent by facsimile or electronic transmission, 
 if to Parent: 
 Ultra Clean Holdings, Inc. 

26462 Corporate Avenue 
 Attention: Casey Eichler 
 Facsimile No.: 510-576-4401 

E-mail: ceichler@uct.com 
 With a copy to: 
 Davis Polk & Wardwell 

1600 El Camino Real 
 Menlo Park, CA 94025 
 Attention: Alan F. Denenberg 

Telephone No.: 650-752-2000 
 Facsimile No.: 650-752-3604 
 E-mail: alan.denenberg@davispolk.com 

if to AIT: 

Houlihan Lokey 

245 Park Avenue 

New York, New York 10167 
 Attention: Dave Salemi 
 Facsimile No.: 212-582-3016 

E-mail: dsalemi@hl.com 
 with a copy to (which shall not constitute notice): 
 Bryan Cave LLP 

3161 Michelson Drive, 15th Floor 
 Irvine, California 92612 
 Attention: Brett J. Souza 

Facsimile No.: 949-223-7100 
 E-mail: bjsouza@bryancave.com 
 All notices, requests and other communications
shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. local time in the place of receipt and such day is a Business Day in the place of receipt. Otherwise, any such notice, request or communication
shall be deemed not to have been received until the next succeeding Business Day in the place of receipt. 

  
 23 

 Any Person that becomes a Stockholder shall provide its name, address and fax number to
Parent. Parent shall not be obligated to provide notice or to include such Person’s Registrable Securities in a registration statement under the provisions of this Agreement to the extent that Parent has not received such information in
sufficient time to fulfill its obligations hereunder. 
 Section 4.04. Waiver; Amendment; Termination. No provision
of this Agreement may be waived except by an instrument in writing executed by the party against whom the waiver is to be effective. No provision of this Agreement may be amended or otherwise modified except by an instrument in writing executed by
all parties hereto. 
 Section 4.05. Governing Law. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York, without regard to the conflicts of laws rules of such state. 
 Section 4.06.
Jurisdiction. The parties hereto agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby (whether
brought by any party or any of its Affiliates or against any party or any of its Affiliates) shall be brought in the state courts located in the State of New York, city of New York, Borough of Manhattan, or, if such court shall not have
jurisdiction, any federal court located in the State of New York, city of New York, Borough of Manhattan, and each of the parties hereby irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in
any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such
suit, action or proceeding brought in any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such
court. Without limiting the foregoing, each party agrees that service of process on such party as provided in Section 4.03 shall be deemed effective service of process on such party. 

Section 4.07. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY
IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

  
 24 

 Section 4.08. Specific Enforcement. Each party hereto acknowledges that the
remedies at law of the other parties for a breach or threatened breach of this Agreement would be inadequate and, in recognition of this fact, any party to this Agreement, without posting any bond, and in addition to all other remedies that may be
available, shall be entitled to obtain equitable relief in the form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy that may then be available. 

Section 4.09. Counterparts; Effectiveness. This Agreement may be executed in any number of counterparts, each of which shall
be deemed to be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received released counterparts hereof signed by all of
the other parties hereto. 
 Section 4.10. Entire Agreement. This Agreement, the Merger Agreement and the Ancillary
Agreements (as defined in the Merger Agreement) constitute the entire agreement among the parties hereto and supersede all prior and contemporaneous agreements and understandings, both oral and written, among the parties hereto with respect to the
subject matter hereof and thereof. 
 Section 4.11. Captions. The captions herein are included for convenience of
reference only and shall be ignored in the construction or interpretation hereof. 
 Section 4.12. Severability. If
any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement
shall remain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon
such a determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner so that the transactions contemplated hereby be consummated as
originally contemplated to the fullest extent possible. 
 [Remainder of page intentionally left blank; signature page
follows] 

  
 25 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by
their respective authorized officers as of the day and year first above written. 
  

					
	ULTRA CLEAN HOLDINGS, INC.
		
	By:	 	 /s/ Kevin C. Eichler

		 	Name:	 	Kevin C. Eichler
		 	Title:	 	Chief Financial Officer, Senior Vice President and Secretary

 [Signature page to Registration Rights Agreement] 

  
 26 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by
their respective authorized officers as of the day and year first above written. 
  

					
	AIT HOLDING COMPANY LLC
		
	By:	 	 /s/ Joseph Julian

		 	Name:	 	Joseph Julian
		 	Title:	 	Chairman

 [Signature page to Registration Rights Agreement] 

  
 27 

 EXHIBIT A 
 JOINDER TO REGISTRATION RIGHTS AGREEMENT 
 This Joinder Agreement (this
“Joinder Agreement”) is made as of the date written below by the undersigned (the “Joining Party”) in accordance with the Registration Rights Agreement dated as of July 3, 2012 (the “Registration Rights
Agreement”) between Ultra Clean Holdings, Inc., and AIT Holding Company LLC, as the same may be amended from time to time. Capitalized terms used, but not defined, herein shall have the meaning ascribed to such terms in the Registration
Rights Agreement. 
 The Joining Party hereby acknowledges, agrees and confirms that, by its execution of this Joinder
Agreement, the Joining Party shall be deemed to be a party to the Registration Rights Agreement as of the date hereof and shall have all of the rights and obligations of a “Stockholder” thereunder as if it had executed the Registration
Rights Agreement as a Stockholder. The Joining Party hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Registration Rights Agreement, as amended as of the date hereof.

  
 28 

 IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the date
written below. 
 Date:                  ,
         
  

			
	[NAME OF JOINING PARTY]
		
	By:	 	  

		 	Name:
		 	Title:

 Address for Notices: 

  
 29EX-10.1

 Exhibit 10.1 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 MANUFACTURING AND SUPPLY AGREEMENT 

THIS MANUFACTURING AND SUPPLY AGREEMENT (the “Agreement”) is made effective as of the 18th day of May 2012 (the
“Effective Date”) by and between Santarus, Inc., a Delaware corporation, having offices at 3721 Valley Centre Drive, Suite 400, San Diego, California 92130, U.S.A. (“Santarus”) and COSMO Technologies Ltd,
a company organised and existing under the laws of Ireland with principal offices and plant located at 42-43 Amiens Street, Dublin 1 Ireland (“Supplier”). Supplier and Santarus are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, Santarus is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products; 

WHEREAS, Supplier is a provider of drug development and commercial manufacturing services to pharmaceutical companies; 

WHEREAS, Santarus and Supplier have entered into that certain License Agreement, dated December 10, 2008 (the “License
Agreement”), granting Santarus exclusive rights to commercialize Finished Commercial Product (as defined below) in the Territory and reserving for Supplier the exclusive right to supply Santarus’ requirements in the Territory; and

 WHEREAS, in accordance with the terms of the License Agreement, Santarus wishes to purchase Finished Bulk Product from
Supplier, and Supplier is willing to manufacture and supply such products to Santarus, on the terms set out in this Agreement. 

NOW THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth below, the Parties agree as follows:

 ARTICLE 1 
 DEFINITIONS 
 1.1 “Affiliate” means any individual,
corporation, association, or other business entity, which directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control”
shall mean, as to an entity, (a) direct or indirect ownership of fifty percent (50%) or more of the voting interests or other ownership interests in the entity in question; (b) direct or indirect ownership of fifty percent
(50%) or more of the interest in the income of the entity in question; or (c) possession, directly or indirectly, of the power to direct or cause the direction of management or policies of the entity in question (whether through ownership
of securities or other ownership interests, by contract or otherwise). 
 1.2 “API” means the active
pharmaceutical ingredient known as budesonide, as specified by Chemical Abstract No. 51333-22-3, manufactured by a Third Party manufacturer and provided to Supplier and/or Manufacturer for use in manufacturing the Finished Bulk Product.

 1.3 “Applicable Laws” mean all laws, statutes, ordinances, codes,
rules, regulations, guidelines, and procedures enacted or made by a Government Authority, including, without limitation, the FDA, that are in force during the Term, and in each case to the extent applicable to the subject matter of, or the
performance by the Parties of their respective obligations under, this Agreement. For purposes of this Agreement, “Applicable Laws” shall include, without limitation, the FFDCA, the regulations promulgated thereunder (including, without
limitation, those regulations currently contained in Title 21 of the Code of Federal Regulations), and other rules and regulations promulgated under the FFDCA relating to the manufacture of pharmaceutical products; equivalent laws, regulations and
standards promulgated by a Government Authority that may assert jurisdiction over the Finished Bulk Product, the Finished Commercial Product or any Facility; cGMP; and the FDA’s regulations for drug establishment registration. 

1.4 “Business Day” means any day other than a Saturday, Sunday or statutory holiday in San Diego, California or
Lainate, Milan, Italy. 
 1.5 “Certificates of Compliance” means (a) the certificate of analysis
confirming the identity, strength, quality and purity of each batch of Finished Bulk Product to which it pertains (together with any certificate of analysis pertaining to the API), (b) the certificate of compliance confirming that each batch of
Finished Bulk Product was manufactured, tested, stored and supplied by Supplier and/or Manufacturer in compliance with this Agreement, including without limitation the Specifications, cGMP and Applicable Laws, and (c) such other certificates
and confirmations as may be described in the Quality Agreement, each such certificate signed by an authorized signatory of Supplier and/or Manufacturer. 
 1.6 “cGMP” means current good manufacturing practices as described in Parts 210 and 211 of Title 21 of the United States Code of Federal Regulations and the requirements imposed
thereunder by the FDA, together with the latest FDA guidance and like documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time. 

1.7 “Deficiency Notice” has the meaning set forth in Section 3.5.1. 

1.8 “Effective Date” has the meaning specified on the first page of this Agreement. 

1.9 “Facility” means Manufacturer’s facilities located at via C.Colombo, 1 20020 Lainate, Milan, Italy, and
any other facilities (including facilities utilized by subcontractors as permitted hereunder) that are used in connection with the activities performed by Supplier, Manufacturer, or its Affiliates or back-up suppliers hereunder. 

1.10 “FDA” means the United States Food and Drug Administration, and any successor thereto. 

1.11 “FFDCA” means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321 et seq., as amended.

  
 2 

 1.12 “Finished Bulk Product” means budesonide MMX 9 mg tablets
manufactured in bulk in accordance with the Specifications. 
 1.13 “Finished Commercial Product” means
the Finished Bulk Product in final packaged form for commercial distribution as trade or sample product. 
 1.14
“Firm Purchase Order” has the meaning set forth in Section 2.3.3. 
 1.15
“Forecast” has the meaning set forth in Section 2.3.2. 
 1.16 “Government
Authority” means any supra-national, national, regional, state, provincial or local government, court, governmental agency, authority, board, bureau, instrumentality or regulatory body having jurisdiction over the Finished Bulk Product, the
Finished Commercial Product or any Facility. 
 1.17 “IND” means any investigational new drug
application filed with the FDA and related to development activities associated with the Finished Commercial Product. 

1.18 “Joint Inventions” means inventions conceived of, discovered, developed, or reduced to practice during the
Term jointly by employees, agents or contractors of Supplier and/or Manufacturer, on the one hand, and Santarus, on the other hand, that relate to Finished Bulk Product or Finished Commercial Product 

1.19 “Joint Patent Rights” means those Patent Rights that relate to or cover Joint Inventions. 

1.20 “Manufacturer” means the Cosmo S.p.A., an Affiliate of Supplier, whose Facility is in Lainate, Via
Cristoforo Colombo 1, Italy and any permitted back-up supplier in accordance with Section 2.12. 
 1.21
“NDA” means the New Drug Application filed with the FDA for marketing approval for the Finished Commercial Product. 
 1.22 “Net Sales” shall have the meaning assigned to such term in the License Agreement. 
 1.23 “Patent Rights” means (a) patents and patent applications, including divisionals, continuations, continuations-in-part, and any foreign counterparts thereof,
(b) those patents or patent applications claiming priority to or through any patent or patent application described in (a), (c) all patents issuing from patent applications included in (a) and (b); and (d) all reissues,
reexaminations, renewals, and extensions of any patents included in (a) through (c). 
 1.24
“Patents” shall have the meaning ascribed to it in the License Agreement. 
 1.25 “Quality
Agreement” means that certain Quality Agreement to be entered into by and between Santarus and Manufacturer within [***] days following the date of this Agreement, and as amended thereafter from time to time. 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 3 

 1.26 “Raw Materials” has the meaning set forth in Section 7.1.

 1.27 “Regulatory Approval” means, with respect to a particular jurisdiction, (a) any approvals,
licenses, registrations, or authorizations necessary for the manufacture (where relevant), marketing and sale of the Finished Bulk Product or Finished Commercial Product in such nation or jurisdiction. 

1.28 “Responsible Executive” means the President or the Chief Executive Officer of a Party, or his or her
designated representative. 
 1.29 “Santarus Inventions” means inventions conceived of, discovered,
developed, or reduced to practice during the Term solely by employees, agents or contractors of Santarus that relate solely to Finished Bulk Product or Finished Commercial Product 

1.30 “Santarus Patent Rights” means Patent Rights that claim or cover Santarus Inventions. 

1.31 “Specifications” means the specifications for the Finished Bulk Product together with applicable
manufacturing protocols, testing methodologies and all applicable requirements set forth in regulatory filings made with, and as applicable approved by, the FDA (including INDs and NDAs) for the Finished Bulk Product, as may be set forth in the
Quality Agreement or otherwise communicated in writing by Santarus to Supplier and/or Manufacturer. 
 1.32
“Supplier Inventions” means inventions conceived of, discovered, developed, or reduced to practice during the Term solely by employees, agents or contractors of Supplier or Manufacturer that relate to Finished Bulk Product or
Finished Commercial Product. 
 1.33 “Supplier Manufacturing Responsibilities” has the meaning specified
in Section 3.1 of this Agreement. 
 1.34 “Supplier Patent Rights” means Patent Rights that claim
or cover Supplier Inventions. 
 1.35 “Term” has the meaning set forth in Section 11.1. 

1.36 “Territory” means the United States of America and all of its territories and possessions, including Puerto
Rico. 
 1.37 “Third Party” means any individual or entity other than Supplier, Manufacturer or Santarus
or their respective Affiliates. 
 1.38 “Unit” means one (1) tablet of the Finished Bulk Product.

 ARTICLE 2 
 SUPPLY, STORAGE, AND DELIVERY OF FINISHED BULK PRODUCT 
 2.1 Supply of
Finished Bulk Product. During the Term, Supplier, through its Affiliate, Manufacturer, shall manufacture and supply, in accordance with the provisions of this 

  
 4 

 
Agreement, the Specifications, cGMP and Applicable Laws, all quantities of the Finished Bulk Product ordered by Santarus pursuant to this Agreement. Supplier shall be responsible for and shall
guaranty the performance of Manufacturer hereunder, and Supplier and Manufacturer shall be jointly and severally liable for any breaches of representations, warranties or covenants hereunder. 

2.2 Exclusivity. During the Term, Santarus shall purchase its requirements of Finished Bulk Product exclusively from Supplier and
Manufacturer, and Supplier and Manufacturer shall manufacture and supply Finished Bulk Product for commercialization in the Territory exclusively to Santarus. 
 2.3 Commercial Supply. 
 2.3.1 Supply Obligations. Supplier shall
have Manufacturer manufacture and supply to Santarus, and Santarus agrees to purchase from Supplier, such quantities of Finished Bulk Product specified by Santarus in accordance with this Agreement at the Price (as defined in Article 6 below).

 2.3.2 Forecasts. 
 (i) Santarus shall use commercially reasonable efforts to determine its estimated requirements for Finished Bulk Product from Supplier and shall deliver to Supplier a written, non-binding, rolling
eighteen (18) month forecast, by month, of such estimated requirements (the “Forecast”). Santarus shall, in accordance with the terms of this Agreement, update and revise the Forecast on a monthly basis. Santarus shall provide
each updated Forecast not less than [***] days prior to the beginning of the next month. The first three (3) months of the Forecast shall be binding on Santarus and cannot be amended by greater than [***] as compared to the prior
Forecast without the prior written consent of Supplier. Supplier shall use the Forecast for planning purposes and make available the production capacity and associated testing and release capacity required to manufacture and supply the forecasted
quantities of Finished Bulk Product. Notwithstanding the foregoing, the Parties shall reasonably cooperate during the [***] period prior to and following initial launch of the Finished Commercial Product to provide additional flexibility for
increases or decreases in Firm Purchase Orders. 
 2.3.3 Firm Purchase Orders. Santarus shall submit to Supplier a firm,
written purchase order (the “Firm Purchase Order”) for the purchase of Finished Bulk Product at least [***] days prior to the specified delivery date, which order shall be consistent with the binding portion of the Forecast,
unless otherwise agreed by the Parties. Santarus shall submit Firm Purchase Orders on a monthly basis. Each Firm Purchase Order shall specify the quantities of Finished Bulk Product ordered, the requested delivery date or dates, the delivery
address(es) and any applicable shipping information. Supplier shall cause Manufacturer to manufacture and supply the Finished Bulk Product in the quantities and by the delivery dates set forth in the applicable Firm Purchase Order. 

2.3.4 Firm Purchase Order Amendments. Santarus may amend a Firm Purchase Order by submitting an amended Firm Purchase Order, as
follows: (i) at least [***] days before the originally scheduled delivery date specified in the Firm Purchase Order, Santarus may amend 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 5 

 
the Firm Purchase Order to delay the delivery date to a date within [***] days of the originally scheduled delivery date; or (ii) at least [***] days before the originally scheduled delivery
date specified in the Firm Purchase Order, Santarus may increase or decrease the quantity of Finished Bulk Product ordered and/or accelerate or delay the delivery date to a date within [***] days of the originally scheduled delivery date, subject to
all commercially reasonable efforts of Supplier and Manufacturer to meet these amended Firm Purchase Orders. 
 2.4 Shipping
and Delivery of Finished Bulk Product. All deliveries of Finished Bulk Product shall be made to Santarus EXW Manufacturer’s Facility (Incoterms 2010). Supplier shall introduce to Santarus an Italian specialized organization who will, as
agent for Santarus, (i) arrange for shipping and insurance so that the Finished Bulk Product will be delivered to the delivery address on the delivery date set forth in the applicable Firm Purchase Order, at Santarus’ expense, and
(ii) obtain any necessary import licenses, certificates of origin or other requisite documents, and pay all applicable customs, duties and taxes in respect of the importation of the Finished Bulk Products into the Territory and their sale in
the Territory. Santarus may select the freight carrier used by Supplier or Manufacturer to ship Finished Bulk Product and may monitor Supplier’s and Manufacturer’s shipping and freight practices as they pertain to this Agreement. Finished
Bulk Product shall be transported in accordance with the Specifications, cGMP and Applicable Laws. Supplier shall notify Santarus in writing at the time of shipment as to the quantity of Finished Bulk Product shipped, the identity of the carrier and
the anticipated delivery date. If any order is delayed and is not likely to be delivered on time, Supplier shall immediately notify Santarus and Santarus may direct Supplier to ship such order by expedited means of transportation as designated by
Santarus. To the extent that any such delay is due to any action or failure to act of Supplier or Manufacturer or otherwise due to matters within Supplier’s or Manufacturer’s control, Supplier shall bear the expense of any difference in
cost for the expedited means of transportation. 
 2.5 Title and Risk of Loss. Supplier shall make the Finished Bulk
Product available to the carrier selected by Santarus at Manufacturer’s Facility unless otherwise mutually agreed in writing. Such title as Supplier or Manufacturer has in Finished Bulk Product and risk of loss or of damage to Finished Bulk
Product shall remain with Supplier or Manufacturer until Finished Bulk Product are loaded onto the carrier’s vehicle by Supplier or Manufacturer for shipment at Supplier’s or Manufacturer’s shipping point at which time title and risk
of loss or damage shall transfer to Santarus. Except as expressly provided otherwise in this Agreement, Santarus shall be responsible for all charges associated with shipping of Finished Bulk Product. 

2.6 Invoices. Supplier shall invoice Santarus on the date of shipment of the Finished Bulk Product for the Base Supply Price,
in accordance with the provisions of Article 6 hereof.
 2.7 Documentation and Customs. Upon completion of manufacturing
and testing of Finished Bulk Product pursuant to each Firm Purchase Order, Supplier shall deliver or have Manufacturer deliver to Santarus by electronic means all requested quality documentation for such Finished Bulk Product manufactured pursuant
to such Firm Purchase Order as specified in the Quality Agreement, including without limitation, the Certificates of Compliance in respect of such Firm Purchase Order and, if requested by Santarus, completed batch production records (collectively,
the “Pre-shipping Documentation”). Supplier acknowledges and agrees that Santarus shall be responsible, at all times, for the final release of the Finished Bulk Product and 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 6 

 
accordingly, neither Supplier nor Manufacturer shall ship any Finished Bulk Product until Santarus has notified Supplier or Manufacturer in writing that it has completed its final release.
Concurrent with the shipment of each Firm Purchase Order of Finished Bulk Product, the Agent/Carrier shall deliver to Santarus the customs documentation corresponding to such shipment and such other documentation and information as may be necessary
or desirable for complying with import, export, and customs laws, regulations and like requirements, as applicable. All Finished Bulk Product, including its packaging, shall meet all applicable export and customs laws, regulations and like
requirements of the country where Manufacturer has its seat and, in respect of the United States, shall be in accordance with the instructions of Santarus in respect of all applicable import and customs laws, regulations and like requirements for
the United States. 
 2.8 Late Delivery/Shortages and Overages. If a shipment of Finished Bulk Product ordered by
Santarus under this Agreement has not been delivered at the shipping point within [***] Business Days after the scheduled delivery date (any delivery that is more than [***] Business Days after the scheduled delivery date stated on the corresponding
Firm Purchase Order is hereinafter referred to as a “Late Shipment”), or if the shipment received by Santarus contains less than [***] of the quantity specified in the corresponding Firm Purchase Order (a “Short
Shipment”), Santarus shall notify Supplier promptly upon such discovery and, in any event, not later than [***] days after receipt of, or failure to receive, such ordered Finished Bulk Product. Supplier shall, and shall cause Manufacturer
to, use its best efforts to deliver the quantity of Finished Bulk Product it had failed to ship in the case of a Late Shipment or the quantity by which the shipment is short of the quantity ordered in the case of a Short Shipment, as soon as
possible after notification of such shortage, by expedited means of transportation at Supplier’s expense in respect of any difference in cost for such expedited means of transportation relative to regular delivery costs. If any shipment
contains more than the quantity ordered, Santarus may elect either to: (a) return to Supplier, at Supplier’s expense, the excess of the quantity ordered, or (b) accept any excess quantity ordered and reserve the right to deduct such
excess from future orders. Santarus shall have no obligation to receive any quantity of Finished Bulk Product in excess of that ordered. In the event of a Raw Material shortage or shortage due to manufacturing outages or shortfalls, Supplier will,
and will cause Manufacturer to, provide equitable share of such Raw Material to Santarus as a percentage of firm orders received. 
 2.9 Key Performance Indicators. 
 2.9.1 For each quarterly period during
the Term, Supplier shall cause Manufacturer to meet or exceed the written key performance indicators established in good faith by Supplier and Santarus for such quarterly period (collectively, as established with respect to the applicable quarterly
period, the “KPIs”). The KPIs shall be mutually agreed to from time to time by the Parties and the Parties shall review such KPIs at each quarterly review meeting contemplated by Section 2.11 with the intention of amending, if
necessary, the KPIs in respect of the forthcoming quarterly period. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 7 

 2.9.2 In the event that Supplier or Manufacturer fails to meet one or more of the KPIs at
any time during the term of this Agreement, then Supplier and Santarus shall work diligently to address such failure including, without limitation, the following: 
 (i) Manufacturer’s Qualified Person and the Senior Director of Contract Manufacturing of Santarus (or such other individual designated by Santarus) shall discuss within [***] days of the
determination of the failure in order to establish a procedure to address the problem (the “Remediation Plan”). If such discussion does not occur within such [***] days or if there is no agreement as to the Remediation Plan
(a “Stage 1 Failure”), then clause (ii) shall apply; 
 (ii) Manufacturer’s Qualified Person and
Santarus’ Senior Vice President, Product Development and Manufacturing will discuss within [***] days of the Stage 1 Failure in order to establish a Remediation Plan. If such discussion does not occur within such [***] days or if
there is no agreement as to the Remediation Plan (a “Stage 2 Failure”), then clause (iii) shall apply; and 
 (iii) Supplier’s Responsible Executive and Santarus’ Responsible Executive shall discuss within [***] days of the Stage 2 Failure in order to establish a Remediation Plan. 

If the Remediation Plan is either not mutually agreed upon or is not implemented satisfactorily, then the Parties may pursue additional dispute
resolution and recourse in accordance with Article 13. The Parties may mutually agree to extend any of the time periods referenced in this Section 2.9. 
 2.9.3 Notwithstanding anything to the contrary in this Section 2.9, Supplier shall not be responsible for the failure to achieve the KPIs to the extent caused by any of the following events:

 (i) Santarus’ failure to deliver Forecasts in accordance with Section 2.3.2; 

(ii) Santarus’ failure to timely deliver amended Specifications in the event that the Specifications are amended pursuant to
Section 3.6.1 or 3.6.2; 
 (iii) Santarus’ failure to deliver the Firm Purchase Orders in accordance with Sections
2.3.3 and 2.3.4; or 
 (iv) Santarus’ failure to timely complete the final release of the Finished Bulk Product in the
absence of any production or quality issues. 
 2.10 Storage of Finished Bulk Product. Until Finished Bulk Product is
shipped, Supplier shall have Manufacturer store all Finished Bulk Product identifiably distinct from any other raw material and finished or filled product stocks and shall comply with all storage requirements set forth in the Specifications.
Supplier shall assume responsibility for any loss or damage to such Finished Bulk Product while stored by Supplier or Manufacturer. 
 2.11 Cooperation and Quarterly Review. Each Party shall forthwith upon execution of this Agreement designate those of its employees to be part of the team responsible for 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 8 

 
managing the relationship between the Parties (the “Relationship Team”). The Relationship Team from each Party shall meet in person or by telephone or video conference not less
than quarterly to review the current status of the manufacturing relationship (including performance against the KPIs as well as any additional manufacturing performance indicators established by the Parties) and address any issues that have arisen.

 2.12 Protection in the event of failure to supply. Supplier and Manufacturer shall consult with and keep Santarus
reasonably informed concerning any potential inability to supply and related remediation and back-up supply activities. Supplier shall store in a location different from that of Manufacturer and compliant with all storage requirements set forth in
the Specifications a quantity of Finished Bulk Products capable to cover not less than [***] months of supply requirements according to the most recent Forecast. All expenses related to such storage, including transportation to and from the
Facility, shall be borne by Supplier. In the event of a failure to supply whose effects may extend over a [***] months or greater time frame in the reasonable judgment of Supplier and Santarus, Supplier shall: a) select a second manufacturer
(“Back-Up Manufacturer”) and ensure that such Back-Up Manufacturer has all necessary Regulatory Approvals to fulfill the obligations of Supplier and Manufacturer hereunder; b) transfer to Back-Up Manufacturer all information and
technology required to manufacture Finished Bulk Products; and c) have Back-Up Manufacturer be ready to manufacture the Finished Bulk Products at the terms and conditions set forth by this Agreement in such a time frame to avoid any Finished Bulk
Products shortage. All expenses related to the selection of the Back-Up Manufacturer, the information and technology transfer and the set-up of supply, and obtaining regulatory approvals therefor, shall be borne by Supplier. Supplier retains the
right to transfer the manufacture of Finished Bulk Products back to Manufacturer as soon as it is able to resume manufacturing. Should Supplier or any of its Affiliates set-up a back-up facility for the purpose of manufacturing Finished Bulk
Products, Supplier shall be entitled to transfer to such back-up facility a reasonable part of the supply at its own cost and expenses, subject to obtaining all necessary Regulatory Approvals therefor. Santarus shall provide reasonable assistance to
Supplier in connection with ensuring that appropriate Regulatory Approvals for the activities hereunder are obtained and maintained. 
 ARTICLE 3 
 STANDARDS OF MANUFACTURE 

3.1 Finished Bulk Product. Supplier hereby covenants on behalf of itself and Manufacturer that all Finished Bulk Product
manufactured and supplied to Santarus under this Agreement: (a) shall have been manufactured, packaged, tested and stored in compliance with the Specifications, cGMP, Applicable Laws and the terms and conditions of this Agreement and the
Quality Agreement; (b) shall not be adulterated, or misbranded within the meaning of the FFDCA or other Applicable Laws as of the time that the Finished Bulk Product is delivered to the carrier at Supplier’s or Manufacturer’s shipping
point; and (c) shall be shipped not more than [***] months from the start of its manufacture, as defined as issuance of API into the process. The foregoing obligations are referred to in this Agreement as the “Supplier Manufacturing
Responsibilities.” 
 3.2 Manufacturing Facility. Supplier will have Manufacturer manufacture Finished Bulk
Product at the Facility. Supplier shall not, either itself or through Manufacturer or any 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 9 

 
other Affiliate, manufacture any Finished Bulk Product in any other facility without first obtaining all necessary or appropriate Regulatory Approvals and Santarus’ prior written consent,
such consent not to be unreasonably withheld. 
 3.3 Testing and Release by Supplier. Prior to shipping (or temporarily
storing, if requested by Santarus) any order, Supplier shall have Manufacturer test each batch of Finished Bulk Product manufactured under this Agreement, and Raw Materials used for such batch, for conformity with the Specifications
(“Supplier Release Testing”). Supplier shall have Manufacturer conduct all such Supplier Release Testing in accordance with the procedures and using the analytical testing methodologies set forth in the Specifications and the
Quality Agreement. Santarus shall be responsible, at all times, for the final release of the Finished Bulk Product, and neither Supplier nor Manufacturer shall ship any Finished Bulk Product until Santarus has completed its release. Supplier shall
have Manufacturer retain sufficient quantities of all shipped Finished Bulk Product and Raw Materials to perform at least full duplicate quality control testing. Retained repository samples of all shipped Finished Bulk Product and Raw Materials
shall be maintained in a suitable storage facility until [***] after expiry of the Finished Bulk Product lot in which the material was used or such longer period as may be required by Applicable Laws. If materials are used in several lots of
Finished Bulk Product, retained repository samples shall be maintained as set forth above until [***] after expiry of the last Finished Bulk Product lot in which such material was incorporated, or such longer period as may be required by Applicable
Laws. All such samples shall be available for inspection and testing by Santarus at reasonable intervals upon reasonable notice. 
 3.4 Stability Studies. As part of its manufacturing obligations, Supplier shall have Manufacturer conduct stability studies on each of the Finished Commercial Products according to the
Specifications therefore, at Supplier’s expense and at no additional charge to Santarus, as required by the FDA or Government Authorities as advised by Santarus or as requested by Santarus, and in any case on at least one batch of Finished
Commercial Product from the Facility at least [***] per [***] or more frequently as may be specified in the Quality Agreement. Supplier shall provide to Santarus a report of all results and data obtained from such stability studies annually or more
frequently as may be specified in the Quality Agreement. 
 3.5 Acceptance Procedures. 

3.5.1 Finished Bulk Product Claims. Santarus has the right to reject any portion of any shipment of Finished Bulk Product that
deviates from the Supplier Manufacturing Responsibilities, without invalidating any remainder of such shipment. Santarus or its agent shall visually inspect the Finished Bulk Product manufactured by Supplier and Manufacturer upon receipt thereof and
shall give Supplier written notice (a “Deficiency Notice”) of all claims for Finished Bulk Product that deviate from the Supplier Manufacturing Responsibilities within [***] days after Santarus’ receipt thereof (or, in
the case of any defects not reasonably susceptible to discovery upon receipt by visual inspection of the Finished Bulk Product, including those requiring laboratory analysis, within [***] days after discovery thereof by Santarus). Should
Santarus fail to provide Supplier with the Deficiency Notice within the applicable [***]–day period, then the delivery shall be deemed to have been accepted by Santarus on the [***] day after delivery or discovery, as applicable.

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 10 

 3.5.2 Determination of Deficiency. Upon receipt of a Deficiency Notice, Supplier
shall have [***] days to advise Santarus by notice in writing that it disagrees with the contents of such Deficiency Notice. If Santarus and Supplier fail to agree within [***] days after Santarus’ receipt of Supplier’s
notice as to whether any Finished Bulk Product identified in the Deficiency Notice deviates from the Supplier Manufacturing Responsibilities, then the Parties shall mutually select an independent laboratory to evaluate if the Finished Bulk Product
deviates from the Supplier Manufacturing Responsibilities. No product testing outside of the approved methods and procedures identified in the Quality Agreement or product NDA shall be performed by the Supplier, Manufacturer or any Third Party test
laboratory without concurrence by both Parties. Such evaluation shall be binding on the Parties, and if such evaluation certifies that any Finished Bulk Product deviates from the Supplier Manufacturing Responsibilities, Santarus may reject such
Finished Bulk Product in the manner contemplated in this Section 3.5. If such evaluation does not so certify in respect of any such Finished Bulk Product, then Santarus shall be deemed to have accepted delivery of such Finished Bulk Product on
the [***] day after delivery (or, in the case of any defects not reasonably susceptible to discovery upon receipt by visual inspection of the Finished Bulk Product, including those requiring laboratory analysis, on the [***] day after
discovery thereof by Santarus). The expenses of such testing shall be borne by Supplier if the non-conformity with the Supplier Manufacturing Responsibilities is confirmed, and otherwise by Santarus. The Parties mutually agree that they shall
resolve all determinations of deficiencies as quickly as possible, and in any event, within [***] days of a Deficiency Notice. 
 3.5.3 Supplier Responsibility. In the event Santarus rejects Finished Bulk Product in accordance with this Section 3.5 and the rejected Finished Bulk Product is determined not to conform to
the Supplier Manufacturing Responsibilities, Supplier shall promptly, at Santarus’ election, either: (i) refund the invoice price for such defective Finished Bulk Product; (ii) offset such amount against other amounts due to Supplier
hereunder; or (iii) replace such Finished Bulk Product with conforming Finished Bulk Product as soon as reasonably possible without Santarus being liable for payment therefor. Nothing in this Section 3.5.3 shall be construed to limit the
rights and remedies available to Santarus at law or in equity. 
 3.6 Specification Amendments. 

3.6.1 Cooperation. The Parties shall cooperate with each other to amend or supplement the Specifications to the extent necessary
to comply with changes in cGMP, Applicable Laws or other requirements of Government Authorities. If an amendment to the Specifications requires FDA approval and/or the approval of another Government Authority, neither Supplier nor Manufacturer shall
implement such change unless and until the necessary approval has been obtained by Santarus in writing. In no event shall Supplier implement or have Manufacturer implement any other modification or addition to the Specifications, including without
limitation, changes in Raw Materials, equipment or methods of production or testing for the Finished Bulk Product, without the prior written consent of Santarus, which consent may be withheld in Santarus’ sole and absolute discretion.

 3.6.2 Santarus’ Request for Change. Santarus shall have the right to amend the Specifications from time to time.

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 11 

 3.6.3 Supplier’s Request for Change. If Supplier wishes to make any change to
the Specifications, Supplier shall notify Santarus, and such notice shall describe the proposed change and the impact of such change on the manufacturing process, including details of any changes in manufacturing costs. Santarus may accept or
reject, in its sole and absolute discretion, any such change proposed by Supplier. 
 3.6.4 Cost. For clarity, Supplier
shall bear all manufacturing and supply related costs associated with amending, supplementing, or changing the Specifications. 

3.7 Records. Supplier shall have Manufacturer maintain all records necessary to comply with cGMP and Applicable Laws relating to
the manufacture, packaging, testing, storage and shipment of Finished Bulk Product. All such records shall be maintained for such period as may be required by Applicable Laws; provided, however, that all records relating to the manufacture,
stability and quality control of each batch of Finished Bulk Product shall be retained until the Parties agree in writing to dispose of such records. 
 3.8 Audit. Upon reasonable prior notice and at reasonable intervals no more than once per year, Supplier shall allow Santarus and its representatives to inspect Supplier’s and
Manufacturer’s books and records relating to the manufacture of the Finished Bulk Product and permit Santarus to access any Facility for the purposes of (a) making quality assurance audits of the facilities and of the procedures and
processes used by Supplier or Manufacturer in manufacturing, packaging, testing, storing and shipping Finished Bulk Product, and (b) confirming Supplier’s and Manufacturer’s compliance with this Agreement, provided that a Supplier
representative is present during any such inspection. Santarus, or its representative(s), shall conduct such audit during normal business hours at a time on which the Parties have mutually agreed, and in such a manner that does not unreasonably
interfere with Supplier’s or Manufacturer’s normal business activities. 
 ARTICLE 4 

REGULATORY MATTERS AND QUALITY CONTROL 
 4.1 Compliance by Supplier. Supplier shall remain in compliance, and shall have Manufacturer remain in compliance, with all Applicable Laws, including cGMP, at all times during the Term and,
without limiting the generality of the foregoing, maintain a quality control program consistent with cGMP as required by the FDA and any other applicable Government Authorities. 

4.2 Santarus’ Regulatory Responsibility. Santarus shall be responsible for obtaining and maintaining the NDA for the Finished
Commercial Product. Supplier will, or will cause Manufacturer to, supply to Santarus from time to time, all such data relating to the Finished Bulk Product and/or Finished Commercial Product, including release test results, complaint test results,
all investigations (in manufacturing, testing and storage), and the like, that Santarus reasonably requires in order to complete any regulatory filing or approval, including any annual product review report that Santarus is required to file with the
FDA and as provided in the Quality Agreement. At Santarus’ request Supplier or Manufacturer will prepare annual product review reports (as further specified in the Quality Agreement) on behalf of Santarus and in accordance with Santarus’
instructions. 

  
 12 

 4.3 Manufacturing Process. If any process event or deviation occurs during the
manufacturing of any Finished Bulk Product, which event is likely to affect the safety, efficacy or regulatory status of the Finished Bulk Product or Finished Commercial Product, then Supplier shall promptly notify Santarus in writing no later than
[***] hours after first discovery by Supplier or Manufacturer. Supplier shall also report or have Manufacturer report to Santarus in writing any other atypical process event or deviation that even though, it may not be perceived to affect the
safety, efficacy or regulatory status of the Finished Bulk Product or Finished Commercial Product, Santarus can assess the potential affect it may have on the cGMP compliance or releasability of the product, Further, Supplier shall, or shall cause
Manufacturer to, fully and appropriately investigate and report to Santarus on all complaints and notices of quality issues concerning the Finished Bulk Product or Finished Commercial Product from the FDA or any other Government Authority of which
Santarus shall have given Supplier notice. Santarus and Supplier shall consult with each other as to the disposition of all affected batches of such Finished Bulk Product or Finished Commercial Product. No API or Finished Bulk Product may be
reprocessed without the prior written consent of Santarus. 
 4.4 Communications. Each Party may communicate with the FDA
or any other Government Authority regarding the Finished Bulk Product if such communication is necessary to comply with the terms of this Agreement or the requirements of any Applicable Law, governmental order or regulation; provided, however, in
the event such requirement applies to Supplier or Manufacturer, Supplier shall notify Santarus in writing of the requirement and pending communication and, unless there is a legal prohibition against doing so, Supplier shall permit Santarus to
accompany Supplier and Manufacturer and take part in any communications with the FDA or any other Government Authority, and to receive copies of all such communications to and from the FDA or any other Government Authority. 

4.5 Government Inspection. 
 4.5.1 Supplier shall make or have Manufacturer make its internal practices, books and records relating to its manufacture of the Finished Bulk Product available and allow or have Manufacturer allow access
to all facilities used for manufacturing the Finished Bulk Product to the FDA and any other Government Authority having jurisdiction over the manufacture of the Finished Bulk Product or Finished Commercial Product for the purposes of determining
Supplier’s and Manufacturer’s compliance with cGMP and Applicable Laws. 
 4.5.2 Supplier agrees to advise or have
Manufacturer advise Santarus by telephone and/or facsimile and/or e-mail immediately of any proposed or announced visit or inspection, and as soon as possible but in any case within [***] hours after any unannounced visit or inspection, by
the FDA or any other Government Authority relating to the Finished Bulk Product. Supplier shall provide Santarus with a reasonable description in writing of each such visit or inspection promptly (but in no event later than [***] days)
thereafter, and with copies of any letters, reports or other documents (including form 483’s) issued by any such authorities that relate to the Finished Bulk Product. Santarus may review Supplier’s and Manufacturer’s responses to any
such reports and communications prior to Supplier or Manufacturer submitting any response to the FDA, or any Government Authority, and Santarus’ comments and suggestions shall, in Supplier’s reasonable discretion, be incorporated into such
response. In no event shall Supplier or Manufacturer commit to any changes to the manufacturing process, equipment, tests and/or specifications concerning the Finished Bulk Product, without Santarus’ prior approval. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 13 

 4.5.3 If the FDA or any other Government Authority conducts an inspection of the Facility in
circumstances that are not related to the manufacturing of the Finished Product (as contemplated by subsection 4.5.2 above) and issues a 483 observation, inspection report or other formal or informal document in respect of such inspection which
questions Supplier’s or Manufacturer’s compliance with cGMP standards relating to operations at the Facility which otherwise could have an adverse impact on the Finished Bulk Product or Finished Commercial Product then Supplier shall
notify Santarus promptly (but in no event later than [***] days) after Supplier or Manufacturer first receives a written copy of such observation, report or document. 
 4.5.4 Supplier and Manufacturer shall keep Santarus informed of (i) the remediation plan Supplier or Manufacturer adopts to alleviate any concerns raised by the FDA or any other Government Authority
contemplated by Sections 4.5.2 or 4.5.3, (ii) progress in implementing the remediation plan and (iii) the formal responses of the FDA or other Government Authority to such remediation plan and its implementation. 

4.6 Environmental and Other Laws and Regulations. In carrying out its obligations under this Agreement, Supplier shall comply and
have Manufacturer comply with all applicable environmental and health and safety laws (current or as amended or added), and shall be solely responsible for determining how to comply with same in carrying out these obligations. 

4.7 Facility Permits and Licenses. Supplier shall obtain and maintain and shall have Manufacturer obtain and maintain all
necessary licenses, permits and governmental approvals (except for product-related Regulatory Approvals such as NDA’s) required to perform its manufacturing and supply services hereunder, including licensure and permitting of its manufacturing
facilities by the FDA and other Government Authorities. 
 4.8 End-User Inquiries and Complaints. Subject to
Supplier’s and Manufacturer’s obligation to report certain information on a more expedited basis in respect of Adverse Experiences as described in Section 5.1 below, Supplier shall notify and refer to Santarus, within [***] Business
Days after receipt, all communications from end-users of the Finished Commercial Product, including without limitation, inquiries regarding the Finished Commercial Product and its uses, and complaints, comments and suggestions regarding the Finished
Commercial Product and its effects on users. Santarus shall have the sole right to respond to all such communications and Supplier and Manufacturer shall provide to Santarus reasonable cooperation and assistance in effecting such responses.

 4.9 Quality Agreement. The Parties shall enter into the Quality Agreement within [***] days following the
execution of this Agreement. 
 ARTICLE 5 
 ADVERSE EVENTS; RECALL 
 5.1 Adverse Experience Reporting. Supplier
shall notify or shall have Manufacturer notify Santarus promptly and not later than [***] hours after Supplier or Manufacturer first becomes aware of (a) any information concerning any potentially serious or 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 14 

 
unexpected side effect, injury, toxicity or sensitivity reaction or any unexpected incidence or other adverse experience (an “Adverse Experience”) and the severity thereof
associated with the use of the Finished Commercial Product, whether or not determined to be attributable to the Finished Bulk Product; or (b) any information regarding any pending or threatened action which may affect the safety or efficacy
claims of the Finished Commercial Product or the continued marketing of the Finished Commercial Product in any nation or jurisdiction. Further and without limiting the foregoing, Supplier shall have Manufacturer notify Santarus by telephone and
facsimile within [***] hours after Supplier or Manufacturer first becomes aware of any serious Adverse Experience that gives cause for concern or is unexpected or that is fatal, life-threatening (as it occurred), permanently disabling, requires (or
prolongs) inpatient hospitalization, represents a significant hazard, or is a cancer or a congenital anomaly or represents an overdose, or any other circumstance that might necessitate a recall, expedited notification of FDA or any other relevant
Government Authorities or a significant change in the label of the Finished Commercial Product, including, without limitation, information concerning any incident that causes Finished Commercial Product or its labeling to be mistaken for or, applied
to, another product, information concerning any bacteriological contamination, or any significant chemical, physical, or other change or deterioration in the Finished Bulk Product, or any failure of one or more batches of Finished Bulk Product
shipped to Santarus to meet Specifications or to conform with Applicable Laws, and any deviation from the specified environmental conditions for shipping or storage of the Finished Bulk Product. To the extent that Santarus becomes aware of any
Adverse Experience that appears to be related to the manufacture of Finished Bulk Product, Santarus shall notify Supplier promptly and not later than [***] hours after Santarus becomes aware of such Adverse Experience. In connection with any such
Adverse Experience, each Party shall make such reports as are necessary to comply with Applicable Laws, at its sole expense. Further, in the event a Party (or its Affiliates) receives a communication or directive from a Government Authority
commencing or threatening seizure of Finished Commercial Product, or other removal from the market of Finished Commercial Product, such Party shall transmit such information to the other Party within twenty-four (24) hours of receipt.

 5.2 Notification and Recall. The handling of recalls and withdrawals of Finished Commercial Product shall be within
the sole discretion of Santarus (as the NDA holder), unless otherwise required by Applicable Laws. If any Government Authority issues or requests a recall or takes similar action in connection with Finished Commercial Product, or if Santarus
determines that an event, incident or circumstance has occurred which may reasonably result in the need for a recall or market withdrawal (collectively, “Recalls”), Santarus shall, within [***] hours, advise Supplier thereof by
telephone or facsimile or e-mail, after which the Parties shall promptly discuss and work together to effect an appropriate course of action. If Supplier or Manufacturer anticipates that a Recall may be necessary, Supplier shall notify and consult
with Santarus as soon as it has notice of the reasons for the Recall, such notification to be given within [***] hours. Notification to FDA (or such other Government Authority) and conducting such Recall shall be the responsibility of Santarus.
Supplier and Manufacturer shall cooperate fully with Santarus in the event of any such Recall of any affected Finished Commercial Product. 
 5.3 Recall Expense. Supplier shall bear the full and reasonable expenses of both Parties and Manufacturer incurred in any Recall to the extent resulting from a failure of Supplier, Manufacturer or
their respective suppliers or subcontractors to manufacture the Finished Bulk Product or the Raw Materials (including the API) in accordance with the Supplier Manufacturing 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 15 

 
Responsibilities, and in all other circumstances Santarus shall bear the full and reasonable expenses of both Parties incurred in any Recall; provided, however, that neither Supplier nor
Manufacturer shall incur any material expenditures without the prior written consent of Santarus. Such expenses of Recall shall include, without limitation, the expenses of notification and destruction or return of the recalled Finished Commercial
Product, distribution of replacement product and all sums paid by Third Parties for the recalled Finished Commercial Product. Without limiting the foregoing, to the extent any Recall is caused by Supplier or Manufacturer breach of any
representation, warranty or covenant of this Agreement, Supplier and Manufacturer shall be liable for and shall indemnify Santarus against all reasonable costs incurred by Santarus in implementing such Recall, and further, at Santarus’
election, Supplier and Manufacturer shall reimburse Santarus for its packaging costs incurred with regard to the Finished Commercial Product and either (i) replace the volume of recalled Finished Bulk Product as soon as reasonable practicable,
but in no event later than [***] days after the date of the Recall, or (ii) reimburse Santarus in an amount equal to the amount paid by Santarus for the recalled Finished Bulk Product, together with all out-of-pocket expenses related thereto.
Nothing in this Section 5.3 shall be construed to limit the rights and remedies available to Santarus at law or in equity. 

ARTICLE 6 

COMPENSATION; PAYMENT 
 6.1 Price of Finished Bulk Product. Santarus shall pay the Base Supply Price and the Additional Supply Price (each as defined below, and collectively referred to herein as the
“Price”) for the Finished Bulk Product, which Price shall constitute payment in full for such Finished Bulk Product and shall include the cost of all Raw Materials. 

6.1.1 Base Supply Price. Santarus shall pay Supplier a base supply price equal to [***] per Unit (the “Base Supply
Price”) within [***] days following receipt of the invoices issued pursuant to Section 2.6.  
 6.1.2
Additional Supply Price. Santarus shall pay Supplier an additional supply price (the “Additional Supply Price”) equal to (a) ten percent (10%) of Net Sales in the Territory during each quarterly period during the
Term, less (b) the Base Supply Price times the number of Units sold during the same quarterly period. The Additional Supply Price shall be payable in accordance with the terms of Section 4 of the License Agreement. 

6.2 Pre-Launch Shipments. To assist Santarus with preparing for initial commercial launch of the Finished Commercial Product,
Supplier agrees to cause Manufacturer to ship to Santarus [***] lots (approximately [***] Units) of Finished Bulk Product for delivery in [***] (the “Pre-Launch Materials”). Notwithstanding Section 6.1 above, Santarus shall not
be obligated to pay the Price for such Pre-Launch Materials [***]. [***] it shall pay the Price for such Pre-Launch Materials in accordance with Article 6 hereof. [***] Santarus shall be entitled to return the Pre-Launch Materials to Supplier (with
Supplier taking title to such Pre-Launch Materials at the time the materials are loaded onto the carrier’s vehicle by Santarus (or its designee) for shipment at Santarus’ (or its designee’s) shipping point, and Santarus shall be
responsible for only the shipping charges associated therewith). 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 16 

 6.3 Invoicing. Supplier shall send all invoices by email or facsimile to the email
address or facsimile number of the accounts payable personnel designated by Santarus from time to time. Supplier’s invoice shall reference the Firm Purchase Order number, product item code, quantity ordered, quantity shipped, requested delivery
date, lot release date and be sent to the “Bill to” address of Santarus specified on the Firm Purchase Order, and Supplier’s packing list must reference the Firm Purchase Order number and be sent to the applicable “Ship to”
address on the Firm Purchase Order. 
 6.4 Form of Payment. Each Party shall make all payments due the other Party under
this Agreement in U.S. Dollars by wire transfer of immediately available funds to such account notified by the receiving Party from time to time to the other Party in writing. 
 6.5 Taxes. Santarus shall withhold from any payment to Supplier under this Agreement any taxes required to be withheld by Santarus under Applicable Laws. Upon request, Santarus shall provide
Supplier with authority for the withholding obligation, documentation of such withholding and payment in a manner that is satisfactory for purposes of such taxing authority. Any withholdings paid when due hereunder shall be for the account of
Supplier. The Parties acknowledge that Supplier will not be assessing value added tax (or VAT) on Santarus invoices. 
 6.6
Disputed Invoices. In the event that Santarus disputes any amounts under any invoice for Finished Bulk Product supplied by Supplier, such dispute shall be resolved in accordance with Section 3.5 (with respect to non-conformance of Finished
Bulk Product) or otherwise under Article 13. Pending resolution of such dispute, Santarus shall be obligated to pay any amounts under such invoice that are not in dispute. Upon resolution of any such dispute in favor of Supplier, Santarus shall pay
all remaining amounts owing under such invoice within the later of [***] Business Days after such resolution or [***] days after the date of receipt of such invoice. 
 6.7 Packaging Start-Up and Ongoing Costs. Supplier shall reimburse Santarus within [***] days following receipt of invoice for all fees and expenses charged by Santarus’ third party packager
and incurred by Santarus in connection with the set-up, initiation and validation of the packaging process for, as well as ongoing packaging of, the Finished Commercial Product, which includes but is not limited to equipment tooling, change parts,
packaging materials and labels, qualification, validation, and associated third party fees. Santarus will keep Supplier reasonably informed, upon request, concerning its packaging activities. Notwithstanding the generality of the foregoing, Supplier
agrees to cause Manufacturer to ship [***] Units to Santarus (or its designee), free of charge and for delivery in [***], for use in packaging qualification activities. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 17 

 ARTICLE 7 
 RAW MATERIALS 
 7.1 Purchase of Finished Bulk Product Raw Materials.
Supplier shall, or shall cause Manufacturer to, purchase, at its cost and expense, all raw materials and other ingredients, including API, excipients and components for the manufacture and shipment of the Finished Bulk Product (collectively,
“Raw Materials”). 
 7.2 Storage of API and Raw Materials. Supplier shall have Manufacturer receive and
store the API and Raw Materials at Supplier’s storage facility at the Facility with due care and attention to the requirements set forth in the Quality Agreement and in accordance with cGMP and Applicable Laws so as to protect such materials
from loss or damage. Supplier will, or will cause Manufacturer to, track API usage with inventory levels being visible to Santarus. 
 ARTICLE 8 
 CONFIDENTIALITY 

8.1 Confidentiality; Exceptions. The Parties agree that, for the Term and for [***] years thereafter (other than for trade
secrets, for which the confidentiality obligations set forth herein shall last as long as trade secret law shall allow), all non-public, proprietary or “confidential” disclosures, know-how, data, and technical, financial and other
information of any nature whatsoever (collectively, “Confidential Information”), disclosed or submitted, either orally or in writing (including, without limitation, by electronic means) or through observation, by one Party (the
“Disclosing Party”) to the other Party (the “Receiving Party”) hereunder, including, without limitation, the terms of this Agreement, shall be received and maintained by the Receiving Party in strict confidence,
shall not be used for any purpose other than the purposes expressly contemplated by this Agreement, and shall not be disclosed to any Third Party (including, without limitation, in connection with any publications, presentations or other
disclosures). Notwithstanding the foregoing, Santarus may disclose on a need-to-know basis the existence of this Agreement and the terms hereof to any bona fide potential acquirers, corporate partners, investors or financial advisors. The Receiving
Party will promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information. Confidential Information belongs to and shall remain the property of the Disclosing Party.

 8.2 Exceptions. The provisions of this Article 8 shall not apply to any information of the Disclosing Party which can
be shown by competent evidence by the Receiving Party: 
 8.2.1 To have been known to or in the possession of the Receiving
Party prior to the date of its actual receipt from the Disclosing Party; 
 8.2.2 To be or to have become readily available to
the public other than through any act or omission of any Party in breach of any confidentiality obligations owed to the Disclosing Party; 
 8.2.3 To have been disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party which had no obligation to the Disclosing Party not to disclose such information to
others; or 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 18 

 8.2.4 To have been subsequently independently developed by the Receiving Party without use
of or reference or access to the Disclosing Party’s Confidential Information. 
 8.3 Authorized Disclosure. The
Receiving Party may disclose the Disclosing Party’s Confidential Information hereunder solely to the extent (a) approved by the Disclosing Party; or (b) the Receiving Party is legally required to disclose such Confidential
Information, provided, however, that prior to any such required disclosure, the Receiving Party will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure (so that the Disclosing Party may seek a
protective order and or other appropriate remedy or waive compliance with the confidentiality provisions of this Article) and will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed.

 8.4 Return of Confidential Information. The Receiving Party shall keep the Disclosing Party’s Confidential
Information in appropriately secure locations. Upon the expiration or termination of this Agreement, the Receiving Party shall destroy or return to the Disclosing Party, at the Disclosing Party’s written request, all Confidential Information
belonging to the Disclosing Party possessed by the Receiving Party, or its officers, directors, employees, agents and consultants; provided however that a Receiving Party may retain one (1) copy of the Disclosing Party’s
Confidential Information in an appropriately secure location, which by Applicable Laws it must retain, for so long as such Applicable Laws require such retention but thereafter shall dispose of such retained Confidential Information in accordance
with Applicable Laws or this Section 8.4. 
 8.5 Equitable Relief. The Receiving Party agrees that, due to the
unique nature of the Confidential Information, the unauthorized disclosure or use of the Confidential Information of the Disclosing Party may cause irreparable harm and significant injury to the Disclosing Party, the extent of which may be difficult
to ascertain and for which there may be no adequate remedy at law. Accordingly, the Receiving Party agrees that the Disclosing Party, in addition to any other available remedies, shall have the right to seek an immediate injunction and other
equitable relief enjoining any breach or threatened breach of this Agreement. The Receiving Party shall notify the Disclosing Party in writing immediately upon the Receiving Party’s becoming aware of any such breach or threatened breach.

 ARTICLE 9 
 INTELLECTUAL PROPERTY MATTERS 
 9.1 Ownership of Patent Rights.
Supplier shall solely own Supplier Patent Rights. Santarus shall solely own Santarus Patent Rights. Supplier and Santarus shall jointly own Joint Patent Rights. 
 9.2 Rights of Santarus under Supplier Patent Rights and Joint Patent Rights. Supplier Patent Rights shall be deemed Patents under the License Agreement. Joint Patent Rights shall be deemed Patents
under the License Agreement with respect to Supplier’s interest in such Joint Patent Rights; provided, however, that such Joint Patent Rights shall be deemed not to contain a Valid Claim for the purposes of Section 1.22 of the License
Agreement. 

  
 19 

 9.3 Santarus Patent Rights. Santarus shall have the sole right, but shall not
be obligated to, file, prosecute, maintain, and enforce Santarus Patent Rights at its sole discretion and expense. Santarus Patent Rights shall be deemed not to contain a Valid Claim for the purposes of Section 1.22 of the License Agreement.

 ARTICLE 10 
 REPRESENTATIONS, WARRANTIES AND COVENANTS 
 10.1 Representations and
Warranties of the Parties. Each Party represents, warrants and covenants to the other Party that: 
 10.1.1 such Party is
duly organized and validly existing and in good standing under the laws of the jurisdiction of its formation; 
 10.1.2 such
Party has the full corporate power and is duly authorized to enter into, execute and deliver this Agreement, and to carry out and otherwise perform its obligations thereunder; 
 10.1.3 this Agreement has been duly executed and delivered by, and is a legal and valid obligation binding upon such Party and the entry into, the execution and delivery of, and the carrying out and other
performance of its obligations under this Agreement by such Party (a) does not conflict with, or contravene or constitute any default under, any agreement, instrument or understanding, oral or written, to which it is a party, including, without
limitation, its certificate of incorporation or by-laws, and (b) does not violate Applicable Law or any judgment, injunction, order or decree of any Government Authority having jurisdiction over it; and 

10.1.4 in connection with its performance under this Agreement, it shall comply with Applicable Laws. 

10.2 Additional Representations, Warranties and Covenants of Supplier. In addition to representations and warranties set forth
elsewhere in this Agreement, Supplier (on behalf of itself and Manufacturer) further represents, warrants to, and covenants with, Santarus that: 
 10.2.1 The Finished Bulk Product shall be manufactured and supplied in accordance with the Supplier Manufacturing Responsibilities. 

10.2.2 At all times during the Term, all parts of the Facility that are associated with the testing and storage of the API and Raw
Materials and the manufacturing, packaging, testing and storage of the Finished Bulk Product shall remain in compliance with all Applicable Laws, and all other parts of the Facility shall remain, in all material respects, in compliance with all
Applicable Laws. 
 10.2.3 Supplier shall have Manufacturer obtain and maintain all necessary licenses, permits or approvals
required by Applicable Laws in connection with the manufacture, packaging, testing and storage of the Finished Bulk Product, including, without limitation, permits related to manufacturing facilities. 

  
 20 

 10.2.4 Manufacturer’s manufacturing facilities are cGMP compliant, licensed and in good
standing with the FDA and any other applicable Government Authority. 
 10.2.5 Supplier has disclosed to Santarus any and all
form 483’s, warning letters or similar notices relating to Manufacturer’s Facility and import alerts for any other products manufactured in such Facility issued during the last five (5) years. 

10.2.6 Title to all the Finished Bulk Product sold hereunder shall pass to Santarus free and clear of any security interest, lien or
other encumbrance. 
 10.2.7 Throughout the Term, Supplier shall have Manufacturer maintain, sufficient facilities, resources,
and a work force suitably qualified and trained to meet its obligations to supply the Finished Bulk Product to Santarus pursuant to this Agreement. 
 10.2.8 None of Supplier, Manufacturer its Affiliates, or any Third Party under its direction or control is: (a) currently excluded from a federal or state health care program under Sections 1128 or
1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as may be amended or supplemented; (b) otherwise currently excluded from contracting with the federal government or (c) otherwise currently excluded, suspended, or
debarred from any federal or state program. Supplier shall immediately notify Santarus if, at any time during the Term, Supplier, Manufacturer, its Affiliates, or any Third Party under its direction or control is convicted of an offense that would
subject it or Santarus to exclusion, suspension, or debarment from any federal or state program in the Territory. 
 10.2.9 The
manufacture of the Finished Bulk Product in accordance with this Agreement does not infringe any Third Party rights (including, without limitation, any intellectual property rights). 

10.2.10 Neither Supplier nor Manufacturer is aware of any pending or threatened claims against Supplier or Manufacturer asserting that
any of the activities of Supplier or Manufacturer relating to the manufacture, import, use, or sale of pharmaceutical products, or the conduct of the activities contemplated herein by Santarus, infringe, misappropriate, or violate the rights of any
Third Party. 
 10.3 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS OR
WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT. 

ARTICLE 11 

TERM AND TERMINATION 
 11.1 Term. This Agreement shall commence as of the Effective Date and shall continue in full force for so long as the License Agreement is in effect, unless otherwise mutually agreed by the
Parties or unless otherwise earlier terminated as set forth herein (the “Term”). 

  
 21 

 11.2 Termination for Cause. In the event that either Party has failed to remedy a
material breach of any of its representations, warranties or other obligations under this Agreement within sixty (60) days (the “Remediation Period”) following receipt of a written notice thereof (the “Breach
Notice”) from the other party that expressly states that it is a notice under this Section 11.2, the non-breaching party may terminate this Agreement upon sixty (60) days’ written notice to the other party (the
“Termination Notice”). For the avoidance of doubt, a material breach of the Quality Agreement shall be deemed to be a breach of this Agreement for the purpose of determining the rights of the Parties to terminate this Agreement.

 11.3 Termination for Bankruptcy. Either Party may terminate this Agreement immediately if the other Party becomes
insolvent, makes a general assignment for the benefit of creditors, suffers or permits the appointment of a receiver for its business or assets, avails itself of or becomes subject to any petition or proceeding under any statute of any state or
country relating to insolvency or the protection of the rights of creditors. 
 11.4 Regulatory Proceedings. Santarus may
terminate this Agreement for one or more of the Finished Bulk Products effective immediately upon written notice to Supplier should the FDA or a Foreign Regulatory Authority having jurisdiction impose on the Facility an import ban in respect of the
Finished Commercial Product or withdraw any license required by Supplier or Manufacturer to manufacture the Finished Bulk Product at the Facility or take other action that is reasonably likely to have a material adverse impact on Supplier’s or
Manufacturer’s ability to perform hereunder. 
 11.5 Government Action. Santarus may terminate this Agreement for
one or more of the Finished Bulk Products upon thirty (30) days’ written notice to Supplier in the event that any governmental agency (including without limitation, the FDA or a Foreign Regulatory Authority) takes any action, or raises any
objection, that prevents Santarus from importing, exporting, purchasing, or selling the Finished Bulk Product and/or Finished Commercial Product or otherwise makes such activity unlawful. 

11.6 Termination for Discontinuation. Santarus may terminate this Agreement for one or more of the Finished Bulk Products if at
any time it decides to no longer market the Finished Commercial Product by giving Supplier six (6) months advance written notice of termination. 
 11.7 Effect of Termination. Except as otherwise provided in this Section 11.7 or elsewhere in this Agreement, in the event this Agreement is terminated for any reason, (a) subject to
Section 11.8, all rights and obligations of the Parties under this Agreement shall terminate; (b) Santarus shall surrender to Supplier, or, at Supplier’s sole option and expense, Santarus shall destroy and provide Supplier with a
certificate signed by a Responsible Executive of Santarus attesting to the destruction of, all copies of any Confidential Information of Supplier in its possession (excluding all of the foregoing assigned to Santarus under Article 9 above);
(c) Supplier shall surrender to Santarus, or, at Santarus’ sole option and expense, Supplier shall destroy and provide Santarus with a certificate signed by a Responsible Executive of Supplier attesting to the destruction of, all copies of
any Confidential Information provided by Santarus hereunder (except to the extent required to be maintained by Supplier pursuant to Applicable Laws or this Agreement); and (d) Santarus shall pay for any of the applicable Finished Bulk

  
 22 

 
Product manufactured at any time before the date of termination pursuant to any Firm Purchase Order delivered to Supplier prior to such termination. Supplier shall cooperate with Santarus and
assist in the transfer to Santarus of all legal and technical documents concerning Raw Materials and Finished Bulk Products, including master batch records, validation reports, stability reports and relevant manufacturer authorizations, existing
retention samples and all such other documents and materials as may be reasonably necessary or useful for Santarus to source the applicable Finished Bulk Products from other qualified Third Parties. 

11.8 Accrued Rights. Termination, relinquishment, or expiration of this Agreement for any reason shall be without prejudice to any
right which shall have accrued to the benefit of either Party prior to such termination, relinquishment, or expiration. Such termination, relinquishment or expiration shall not relieve either Party from obligations which are expressly indicated to
survive termination or expiration of this Agreement. The provisions of this Article 11 shall not limit or restrict the rights of any Party to seek remedies or take measures that may be otherwise available to it at law or equity in connection with
the enforcement and performance of obligations under this Agreement. Any provision of this Agreement intended by their specific terms or by necessary implication to survive the expiration or termination of this Agreement, including without
limitation, Articles 8, 9 and 11-14, shall so survive. 
 ARTICLE 12 

INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY 
 12.1 Indemnification by Santarus. Santarus hereby agrees to defend, at its expense, indemnify, and hold harmless Supplier, its directors, officers, employees, agents, and Affiliates, against all
Third Party claims, demands, damages, liabilities, losses, costs and expenses, including, without limitation, attorney’s fees (collectively, “Claims”) resulting from or arising out of: (a) the negligence or willful
misconduct of Santarus, its Affiliates, or their directors, officers, agents, employees or consultants in the performance of their obligations under this Agreement; (b) a breach by Santarus of any provision of this Agreement or the Quality
Agreement; or (c) a breach by Santarus of any of its representations or warranties set forth in this Agreement or the Quality Agreement; provided, however, that Santarus shall not be obligated to indemnify Supplier under this Section 12.1
to the extent that such Claim results from or arises out of any act or omission for which Supplier is obligated to indemnify Santarus pursuant to Section 12.2 below. 
 12.2 Indemnification by Supplier. Supplier hereby agrees to defend, at its expense, indemnify, and hold harmless Santarus, its directors, officers, employees, agents, and Affiliates against all
Third Party Claims resulting from or arising out of (a) the failure to manufacture, package and test the Finished Bulk Product in accordance with the Supplier Manufacturing Responsibilities; (b) the failure to store the Finished Bulk
Product or Raw Materials in accordance with the Specifications, cGMP and Applicable Laws; (c) the negligence or willful misconduct of Supplier, Manufacturer, its Affiliates, or their directors, officers, agents, employees or consultants in the
performance of their obligations under this Agreement, (d) a breach by Supplier of any provision of this Agreement or the Quality Agreement; or (e) a breach of any of Supplier’s representations, warranties, or covenants set forth in
this Agreement or the Quality Agreement; provided, however, that Supplier shall not be obligated to indemnify Santarus under this Section 12.2 to the extent that such Claim results from or arises out of any act or omission for which Santarus is
obligated to indemnify Supplier pursuant to Section 12.1 above. 

  
 23 

 12.3 Indemnification Procedure. Each indemnified Party (the
“Indemnitee”) agrees to give the indemnifying Party (the “Indemnitor”) prompt written notice of any Claims or discovery of fact upon which the Indemnitee intends to base a request for indemnification.
Notwithstanding the foregoing, the failure to give timely notice to the Indemnitor shall not release the Indemnitor from any liability to the Indemnitee to the extent the Indemnitor is not materially prejudiced thereby. 

12.3.1 The Indemnitee shall furnish promptly to the Indemnitor copies of all papers and official documents in the Indemnitee’s
possession or control which relate to any Claims; provided, however, that if the Indemnitee defends or participates in the defense of any Claims, then the Indemnitor shall also provide such papers and documents to the Indemnitee. The
Indemnitee shall reasonably cooperate with the Indemnitor in defending against any Claims. 
 12.3.2 The Indemnitor shall have
the right, by prompt written notice to the Indemnitee, to assume direction and control of the defense of any Claim, with counsel reasonably satisfactory to the Indemnitee and at the sole cost of the Indemnitor, so long as (a) the Indemnitor
shall promptly notify the Indemnitee in writing (but in no event more than [***] days after the Indemnitor’s receipt of notice of the Claim) that the Indemnitor intends to indemnify the Indemnitee pursuant to this Article absent the
development of facts that give the Indemnitor the right to claim indemnification from the Indemnitee, and (b) the Indemnitor diligently pursues the defense of the Claim. 
 12.3.3 If the Indemnitor assumes the defense of the Claim as provided in this Section 12.3, the Indemnitee may participate in such defense with the Indemnitee’s own counsel who shall be
retained, at the Indemnitee’s sole cost and expense; provided, however, that neither the Indemnitee nor the Indemnitor shall consent to the entry of any judgment or enter into any settlement with respect to the Claim without the
prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. If the Indemnitee withholds consent in respect of a judgment or settlement involving only the payment of money by the Indemnitor and which would
not involve any stipulation or admission of liability or result in the Indemnitee becoming subject to injunctive relief or other relief, the Indemnitor shall have the right, upon written notice to the Indemnitee within [***] days after
receipt of the Indemnitee’s written denial of consent, to pay to the Indemnitee, or to a trust for its or the applicable Third Party’s benefit, such amount established by such judgment or settlement in addition to all interest, costs or
other charges relating thereto, together with all attorneys’ fees and expenses incurred to such date for which the Indemnitor is obligated under this Agreement, if any, at which time the Indemnitor’s rights and obligations with respect to
such Claim shall cease. 
 12.3.4 The Indemnitor shall not be liable for any settlement or other disposition of a Claim by the
Indemnitee which is reached without the written consent of the Indemnitor. 
 12.4 No Consequential Damages. UNDER NO
CIRCUMSTANCES SHALL EITHER PARTY BE RESPONSIBLE OR LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 24 

 
OR OTHER LIKE DAMAGES, OR FOR ANY LOSS OF PROFITS, LOSS OF REVENUE, LOSS RESULTING FROM INTERRUPTION OF BUSINESS OR LOSS OF USE OR DATA, EVEN IF SUCH PARTY, OR ANY OF ITS DIRECTORS, OFFICERS,
EMPLOYEES, OR AGENTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY OF ANY KIND, UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER THEORY, ARISING OUT OF OR
RELATING IN ANY WAY TO THIS AGREEMENT OR ITS IMPLEMENTATION. FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION 12.4 SHALL BE INTERPRETED TO LIMIT THE INDEMNIFICATION OBLIGATION OF EITHER PARTY IN CONNECTION WITH A PRODUCT LIABILITY CLAIM WITH
RESPECT TO THE CHARACTERIZATION OF DAMAGES OR LOSSES CLAIMED BY A THIRD PARTY AS BEING INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE OR OTHER LIKE DAMAGES OR LOSSES. 

12.5 Insurance. Each of Supplier and Manufacturer, on the one hand, and Santarus, on the other hand, shall maintain commercial
general liability through the term of this Agreement and for a period of [***] years thereafter, which insurance shall afford limits of not less than (i) [***] USD ($[***]) for each occurrence, and (ii) [***] USD ($[***]) annual aggregate.
In addition, Santarus shall maintain, and Supplier shall have Manufacturer maintain, product liability insurance through the term of this Agreement and for a period of five (5) years thereafter, which insurance shall afford limits of not less
than (i) [***] USD ($[***]) for each occurrence, and (ii) [***] USD ($[***]) annual aggregate. Supplier shall cause Manufacturer to name Santarus as an additional insurer under Manufacturer’s product liability policy. In addition,
from time to time during the term of this Agreement, each Party shall (and Supplier shall cause Manufacturer to) increase their levels of insurance coverage if reasonably deemed prudent by such party in light of the overall activities under this
Agreement. If requested each Party will provide the other with a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date and the limits of liability. Each
Party shall (and Supplier shall cause Manufacturer to) provide for a minimum of [***] days’ written notice to the insured of a cancellation of, or material change in, the insurance. If a Party (including, in the case of Supplier, Manufacturer)
is unable to maintain the insurance policies required under this Agreement through no fault on the part of such Party, then such Party shall forthwith notify the other Party in writing and the Parties shall in good faith negotiate appropriate
amendments to the insurance provision of this Agreement in order to provide adequate assurances. 
 ARTICLE 13 

GOVERNING LAW; DISPUTE RESOLUTION 
 13.1 Governing Law. This agreement is governed by Italian law without regard to the conflicts of laws and provisions thereof and without regard to the United Nations convention on contracts for the
sale of foods. 
 13.2 Dispute Resolution/Injunctive Relief. Notwithstanding anything to the contrary contained in this
Agreement, the Parties specifically agree to the following dispute resolution procedure. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 25 

 13.2.1 Negotiation Between Responsible Executives. In the event of any dispute
between the Parties arising out of or related to this Agreement, the Parties shall refer such dispute to the Responsible Executive of Santarus and the Responsible Executive of Supplier for attempted resolution by good faith executive negotiations
within [***] days after such referral is made. In the event such officers are unable to resolve such dispute within such [***] day period, then the Parties will subject themselves to the arbitration procedures set forth below before
seeking any other means of resolving the dispute. 
 13.3 Arbitration. In the event of any dispute arising out of
or in connection with this Agreement, the Parties agree that such dispute shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce – ICC by a panel of three arbitrators appointed in accordance with the
said Rules of Arbitration. The arbitrators shall apply Italian Law. The seat of arbitration shall be Paris (France) and the language of the arbitration proceeding shall be English. 

13.3.1 Continuation of Performance. Except where such area of performance is the subject of dispute, each Party shall continue to
perform its respective obligations under this Agreement while any dispute is being resolved in accordance with this Section 13.3 unless and until such obligations are terminated or expire in accordance with the provisions of this Agreement.

 ARTICLE 14 
 MISCELLANEOUS 
 14.1 Assignment. Supplier may not assign this
Agreement or any of its rights or obligations hereunder) without the written consent of Santarus, such consent not to be unreasonably withheld. Santarus may not assign this Agreement or any of its rights or obligations hereunder without the written
consent of Supplier, such consent not to be unreasonably withheld. Notwithstanding the foregoing provisions of this Section 14.1, Santarus may assign this Agreement to any of its Affiliates or to a successor to or purchaser of all or
substantially all of its assets relating to this Agreement. 
 14.2 Force Majeure. With respect to this Agreement,
neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses on account of failure of performance by the defaulting Party if the failure is occasioned by war, fire, explosion, flood, strike, lockout, terrorist
attacks, embargo, act of God, or any other similar cause to the extent beyond the reasonable control of the defaulting Party, provided that the Party claiming force majeure shall promptly notify the other Party in writing setting forth the nature of
such force majeure, shall use its best efforts to eliminate, remedy or overcome such force majeure and shall resume performance of its obligations hereunder as soon as reasonably practicable after such force majeure ceases. Notwithstanding the
previous sentence, if any force majeure continues for more than ninety (90) days, the other Party may terminate this Agreement. 

14.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purpose and intent of this Agreement. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  
 26 

 14.4 Notices. All notices required or permitted to be given under this Agreement
shall be in writing and shall be deemed given if delivered personally or by facsimile transmission receipt verified, mailed by registered or certified mail return receipt requested, postage prepaid, or sent by express courier service, to the Parties
at the following addresses, or at such other address for a Party as shall be specified by like notice, provided that notices of a change of address shall be effective only upon receipt thereof. 

If to Supplier: 

Cosmo Technologies Ltd 
 42-43 Amiens Street 
 Dublin 1 

Ireland 
 Attn:
Giuseppe Cipriano, Director 
 With a copy to: 
 Cosmo S.p.A. 
 via C. Colombo, 1 

20020 Lainate (MI) 
 Italy 
 Attn: Davide Malavasi, Qualified Person 

If to Santarus: 

Santarus, Inc.  
 3721 Valley Centre Drive, Suite 400 
 San Diego CA 92130 

Phone: 858-314-5700 
 Fax: 858-314-5701 
 Attn: Sr. Vice President, Manufacturing and Product Development

 With a copy to: 

Santarus, Inc.  
 3721 Valley Centre Drive, Suite 400 
 San Diego CA 92130 

Phone: 858-314-5700 
 Fax: 858-314-5702 
 Attn: Legal Affairs 

Unless an earlier date can be proven by competent evidence, the date of receipt of any notice given under this Agreement, including, without limitation,
any invoice provided by Supplier to Santarus, shall be deemed to be the date given if delivered personally or by facsimile transmission receipt verified, seven (7) days after the date mailed, if mailed by registered or certified mail return
receipt requested, postage prepaid, and two (2) days after the date sent if sent by express courier service. 

  
 27 

 14.5 Waiver. No failure of either Party to exercise and no delay in exercising any
right, power or remedy in connection with this Agreement (each a “Right”) will operate as a waiver thereof, nor will any single or partial exercise of any Right preclude any other or further exercise of such Right or the exercise of
any other Right. No waiver shall be effective unless made in writing and signed by the waiving Party. 
 14.6 Disclaimer of
Agency. The relationship between Supplier and Santarus established by this Agreement is that of independent contractors, and nothing contained in herein shall be construed to (i) give either Party the power to direct or control the
day-to-day activities of the other, (ii) constitute the Parties as the legal representative or agent of the other Party or as partners, joint venturers, co-owners or otherwise as participants in a joint or common undertaking, or
(iii) allow either Party to create or assume any liability or obligation of any kind, express or implied, against or in the name of or on behalf of the other Party for any purpose whatsoever, except as expressly set forth in this Agreement.

 14.7 Severability. If any term, covenant or condition of this Agreement or the application thereof to any Party or
circumstance shall, to any extent, be held to be invalid or unenforceable by a court or administrative agency of competent jurisdiction, then the remainder of this Agreement, or the application of such term, covenant or condition to Parties or
circumstances, other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each term, covenant or condition shall be valid and be enforced to the fullest extent permitted by law. 

14.8 Entire Agreement. This Agreement, including all schedules and exhibits attached hereto, and the Quality Agreement, which are
hereby incorporated herein by reference, set forth all covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the manufacture and supply of commercial quantities of
Finished Bulk Product and supersedes and terminates all prior and contemporaneous agreements and understandings between the Parties with respect to such subject matter. Notwithstanding the generality of the foregoing, this Agreement is intended to
supersede and replace Article 5 of the License Agreement. 
 14.9 Modification. No subsequent alteration, amendment,
change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. In the event of a conflict between the terms of any Firm Purchase Order, order
acknowledgement, packaging slip or other documentation, and the terms of this Agreement, the terms of this Agreement shall control, unless such documentation specifically states that it overrides conflicting terms of this Agreement and is signed by
each of the Parties. 
 14.10 Construction. This Agreement shall be deemed to have been drafted by all Parties and, in
the event of a dispute, no Party hereto shall be entitled to claim that any provision should be construed against any other Party by reason of the fact that it was drafted by one particular Party. The headings used in this Agreement are for
convenience of reference only and are not a part of the text hereof. 

  
 28 

 14.11 Counterparts. This Agreement may be executed in counterparts, by manual or
facsimile signatures, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 29 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 

 

									
	Cosmo Technologies Ltd	 		 	Santarus, Inc.
					
	By:	 	 /s/ Giuseppe Cipriano
	 		 	By:	 	 /s/ Gerald T. Proehl

					
	Name:	 	 Giuseppe Cipriano
	 		 	Name:	 	 Gerald T. Proehl

					
	Title:	 	 Director
	 		 	Title:	 	 President & CEO

  
 30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]